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A phenomenon called donor-specific hyporesponsiveness (DSH) has been described
in some renal allograft recipients, in which there is progressive loss of responsiveness
to donor tissues and this has been shown to be associated with a favourable long-term
outcome. Despite its potential clinical importance, the mechanisms of DSH are
unknown and there are no laboratory tests that accurately predict its development in
individual patients which might allow the reduction of immunosuppressive therapy.
Here I test the hypothesis that renal allograft recipients with DSH can be identified by
analysis of the mixed lymphocyte reactivity in-vitro and that this state will be
accompanied by the production of inhibitory cytokines such as IL-10 and TGF-p.
The study comprised 78 patients from a single centre, 60 of whom were studied
retrospectively and 18 prospectively over a one-year period. DSH was detected by
donor specific mixed lymphocyte reactions and cytokine production was analysed by
ELISA and PCR. Overall, DSH was found in 61% of cadaveric and 57% of living-
related recipients in the retrospective cohort and in 36% of cadaveric and 25% of
living-related recipients at one year post-transplant in the prospective cohort. DSH
was associated with a lower incidence of late acute rejection in cadaveric and living-
related recipients in both arms of the study. Chronic rejection was found in some
patients, even in the presence ofDSH, indicating that DSH is not exclusive to patients
with a good allograft outcome.
DSH correlated with a good graft outcome in long-term cadaveric recipients and was
associated with low donor-specific IL-2 and high IL-4 production. Similarly, good
graft outcome and DSH was associated with a trend towards low donor-specific IL-2
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and high IL-4 production within the first year post-transplant. However, in long-term
living-related recipients, DSH did not correlate with graft outcome and was
associated only with low IL-2 production. A sub-group of cadaveric recipients with a
de-novo solid organ malignancy shared many similar clinical and immunological
features with their counterparts who did not have malignancy. This included good
graft outcome, low acute rejection rate and a high incidence of DSH. Patients with
malignancy produced low levels of IL-2, but also produced high levels of IL-10.
However, there was no evidence of immune regulation mediated by IL-10 or TGF-(3
in any part of the study.
My results suggest that it may be possible to select patients for tailoring of
immunosuppression on the basis of detection ofDSH, together with the production of
a favourable cytokine profile at one year post-transplant. Potential candidates include
cadaveric recipients with stable graft function who show DSH and produce four-fold
higher levels of donor-specific IL-4 than IL-2, as well as HLA-ID living-related
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CHAPTER 1: GENERAL INTRODUCTION
OBJECTIVES
Renal transplantation has significantly improved the long-term survival and the
quality of life for many patients with end-stage renal failure and has become the
preferred mode of renal replacement therapy. However, the morbidity associated
with long-term immunosuppression remains an important problem. Although
specific immune tolerance to donor alloantigens can readily be induced and
maintained in animal models (Larsen et al, 1996), this has been difficult to achieve in
humans. Nevertheless, in some non-compliant patients and in some of those with
malignancy, excellent graft function can be maintained despite little or no
immunosuppression (Reyes et al, 1993; Ishido et al, 1999; Birkeland et al, 2000).
This suggests that it may be possible to reduce the amount of immunosuppression in
some recipients without inducing rejection episodes and it would be useful to be able
to identify such patients. To achieve this, a reliable method is needed to monitor
immune responses in vitro. Although many strategies have been proposed for this
purpose, few have been used successfully to guide clinical decisions and there
remains no reliable immunological assay that can be used safely to tailor
immunosuppression.
A phenomenon known as donor-specific hyporesponsiveness (DSH) has been
described in which the allograft recipient shows reduced reactivity or non-reactivity
towards donor cells, but retains normal reactivity towards other antigens (Bach et al,
1968; Fletchner et al, 1984; Reinsmoen et al, 1990). Despite its potential clinical
importance, the mechanism by which DSH occurs remains unknown. There is
I
increasing evidence that differential production of cytokines by T cells may be
important in a variety of models of immunological tolerance, but the possibility that
this is associated with DSH has not been widely studied. The purpose of my work
was to develop an immunological method to guide reduction of immunosuppression
by assessing donor-specific proliferative responses and cytokine production in
recipients of renal allografts. I tested the hypothesis that renal allograft recipients
with good graft outcome would show DSH and that this state would be accompanied
by the production of inhibitory cytokines such as IL-10 and TGF~p.
COMPLICATIONS OF RENAL TRANSPLANTATION
Transplantation is not without risk. Early post-operative complications following
renal transplantation may be surgical, medical or immunological. These include
haemorrhage, urinary leaks, delayed graft function, sepsis and acute rejection. As
graft survival has improved in recent years, the long-term medical complications of
transplantation have become increasingly important. The most important of these
include cardiovascular disease, infection, bone disease, and drug-induced diabetes
(Kasiske et al, 2000; Wheeler et al, 2000; Ojo et al, 2000). Malignancy is a further,
highly feared complication, as it often necessitates a reduction of
immunosuppression, sometimes at the expense of graft loss. Death of patients with
functioning grafts accounts for more than 50% of late graft loss and in the surviving
patients, chronic rejection is the commonest cause of graft failure (Joseph et al,
2001).
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Current strategies to prevent late graft loss include improved peri-operative
management, prevention and treatment of acute rejection, discontinuation of steroids
in stable patients and the assessment and treatment of cardiovascular risk factors.
The induction and identification of donor-specific hyporesponsiveness to allow
minimal immunosuppression or the induction and maintenance of tolerance requiring
no maintenance immunosuppression is one strategy of possible future importance
(Pascual et al, 2002). It is this aspect which my study focussed on.
ACUTE REJECTION
Acute rejection may be defined as an unexplained rise in serum creatinine, occurring
most frequently within the first three months post-transplant, that is confirmed on
biopsy or that responds to treatment with corticosteroids (Massy et al, 1995). It is a
T lymphocyte mediated immune response characterised by a mononuclear interstitial
infiltrate with tubulitis and varying degrees of vascular inflammation (Almond et al,
1993). In the acute rejection process, T cell activation occurs predominantly via the
direct pathway of allorecognition, whereby the recipient's T cell receptors (TcR)
recognise intact MHC molecules on the surface of donor cells. This is induced
predominantly by professional antigen presenting cells (APC) such as dendritic cells
(DC) which are abundant in the graft during the early post-transplant period, and
play a key role in antigen-processing and presentation to T cells. Over time, the
number of donor-derived APC in the graft decrease leading to a diminution of the
incidence and severity of acute rejection (Allan et al, 2002). This is reflected in
clinical practice by the observation that the course of a renal transplant is
characterised by an early high probability of acute rejection, followed by a period
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when acute rejection is less common despite lower immunosuppression
(Gourishankar et al, 2001).
Most immunosuppression regimens aim to reduce the incidence of acute
rejection with the anticipation that this would improve long-term graft survival.
Before the introduction of azathioprine in the 1960's, most grafts were lost in the
first year post-transplant as a result of acute rejection. The introduction of
cyclosporin in the mid-1980's led to a further improvement in short-term graft
survival, but it did not solve the problem of late graft loss and it is too early to
determine whether newer immunosuppressive agents will address this issue. A recent
multivariate analysis has shown a 21% difference in 5-year graft survival between
patients with and without a history of acute rejection, suggesting that it is still
important to reduce the incidence of acute rejection (Allan et al, 2002).
Acute rejection increases the risk of developing chronic rejection and
subsequent graft loss. Many factors influence this effect of acute rejection on graft
outcome, in particular the timing, number and severity of acute rejection episodes.
Acute rejection within the first three months post-transplant may have no effect on
chronic rejection (Massy et al, 1996), but after three months confers the greatest risk
(Humar et al, 1999; Joseph et al, 2001). Indeed, patients with no or only early acute
rejection have been shown to have significantly better long-term graft survival than
patients who had acute rejection after the first three months post-transplant (Joseph et
al, 2001; Sijpkens et al, 2003). Patients who experience multiple acute rejection
episodes also have a significantly increased risk of subsequent graft loss (Basadonna
et al, 1993; Monaco et al, 1999; Humar et al, 2000). Severe acute rejection with
vascular injury exerts a more detrimental effect on graft survival than those that
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result in complete functional recovery (Massy et al, 1996; Mueller et al, 2000).
Therefore, long-term graft outcome is dependent both on preventing acute rejection
and on reducing the likelihood of subsequent episodes, both of which are largely
influenced by HLA-matching and optimising immunosuppression. Hence in my
study, good graft outcome was defined on the basis of no or only early steroid
responsive acute rejection occurring within the first three months post-transplant and
the maintenance of good graft function.
CHRONIC REJECTION
Chronic rejection is the slow, insidious and progressive deterioration of renal
function, as evidenced by increasing serum creatinine levels, and generally occurs
more than 90 days post-transplantation (Monaco et al, 1999). Despite modern
immunosuppression and surgical techniques, the incidence of graft loss beyond the
first year remains unchanged at a rate of about 5% each year post-transplantation
(Cecka, 1999; Keck et al, 1999). The immune mechanism of the chronic rejection
process in not fully understood, but allorecognition appears to occur predominantly
via the indirect pathway, whereby alloantigens are processed by recipient APC and
the resulting peptide antigens are presented to host T cells in the context of selfMHC
molecules. As virtually all the parenchymal cells of an allograft can provide a source
of antigens for processing by host APC, indirect allorecognition is a potentially ever-
present mechanism that may sustain long-term alloresponsiveness (Allan et al, 2002).
Many non-immunological factors have also been implicated in the aetiology of
chronic rejection, including hypertension, cyclosporin nephrotoxicity and
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cytomegalovirus infection, all of which may promote vascular injury (Almond et al,
1993; Monaco et al, 1999; Allan et al, 2002).
The criteria for the diagnosis of chronic rejection are not standardised, but the
gradual deterioration in graft function is often associated with proteinuria and
hypertension, together with typical biopsy findings of interstitial fibrosis, glomerular
sclerosis and fibrointimal proliferation in intra-renal arteries. Although there is some
evidence that mycophenolate mofetil can stabilise graft function in patients with
chronic rejection (Weir et al, 1997), most patients invariably progress to end-stage
renal failure. As little can be done to modify the immune process at present, much
attention is paid to addressing the non-immunological risk factors for chronic
rejection in clinical practice. I have studied a group of patients with poor graft
outcome, defined on the basis of biopsy-proven chronic rejection or risk factors for
chronic rejection such as late, multiple or severe acute rejection, to compare the
incidence ofDSH and donor-specific cytokine production in patients without chronic
rejection.
MALIGNANCY
There is an increased risk of malignancy post-transplantation in patients with end-
stage renal failure, with an incidence estimated to be 3- to 4-fold greater than that of
age-matched controls in the general population (Penn, 1998). This is not seen to the
same extent in patients receiving long-term haemodialysis (Birkeland, 2000). Several
mechanisms have been proposed for the high incidence of malignancy associated
with renal transplantation, including defective immune surveillance as a result of
immunosuppression leading to increased susceptibility to virally induced
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malignancies such as Kaposi's sarcoma and cervical carcinoma (Sheil et al, 1991).
Alternatively, some immunosuppressive drugs themselves may be oncogenic, while
agents such as anti-thymocyte globulin and OKT3 which deplete T lymphocytes may
lead to secondary lymphoid hyperplasia and potential dysplasia, thereby increasing
the risk of development of post-transplant lymphoproliferative disorders (PTLD).
The total cumulative immunosuppressive dose is well correlated with the
development ofmalignancy, and patients treated with cytolytic therapy for treatment
of acute rejection are particularly at risk (Silkensen, 2000).
PTLD is a life-threatening complication of transplantation which is dependent
on exposure to the Epstein-Barr virus (EBV), and on the type and duration of
immunosuppression. To my knowledge, this is the only post-transplant malignancy
in which donor reactivity in MLR and donor-specific cytokine production has been
assessed. Birkeland et al (2000) studied the role of IL-10 in the development of
EBV-associated PTLD and proposed that IL-10 may act in an inhibitory capacity to
promote viral infection and cell transformation by reducing NK cell control over B-
cell proliferation, and suggested that IL-10 may also account for the operational
tolerance observed in some patients.
All patients undergoing renal transplantation are made aware of the potential
risk of malignancy and efforts are routinely made to reduce this risk by careful
screening of recipients and close monitoring post-transplantation. Nevertheless,
some patients develop tumours and in the immunosuppressed state, this is frequently
associated with reduced survival. I studied patients who developed a malignancy
post-transplant, as it has been observed that the reduction of immunosuppression in
some patients with malignancy did not lead to acute rejection or graft loss. Hence, I
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wished to test the hypothesis that these patients would be one group that would show
donor-specific hyporesponsiveness and produce inhibitory cytokines in response to
donor stimulation.
IMMUNOSUPPRESSION AND ASSOCIATED PROBLEMS
Much of the morbidity following renal transplantation has been attributed to long-
term immunosuppression. Furthermore, immunosuppressive therapy has its own
limitations, such as drug toxicity and inter-individual variations in sensitivity to the
drugs. The most commonly used immunosuppressants are corticosteroids,
azathioprine and cyclosporin. In clinical practice, these drugs are used as a triple
therapy and they work synergistically, as they interfere with different stages of the
rejection process. Corticosteroids play an important role in the prevention and
treatment of allograft rejection, but they are also responsible for a significant amount
of post-transplant morbidity. Long-term steroid therapy may cause a Cushingoid
appearance, bone disease, diabetes, hyperlipidaemia and adrenal suppression.
Azathioprine is a purine analogue that is incorporated into cellular DNA where it
inhibits purine nucleotide synthesis and consequently T-cell activation. Its most
important side effect is bone marrow suppression. Cyclosporin, a calcineurin
inhibitor which interferes with IL-2 gene transcription, thereby inhibiting T-cell
activation, has improved 1-year allograft survival from 50% to greater than 80%, but
can cause nephrotoxicity and ultimately allograft dysfunction. It may also cause
hypertension, diabetes, gum hypertrophy and hyperkalemia. Therefore, it is not
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surprising that non-compliance with complex and prolonged therapy is a problem
and may adversely affect graft outcome (Gaston et al, 2001).
Combination therapy is used to allow lower doses of individual drugs to be
used, thereby reducing side-effects. Tailoring of immunosuppression to reduce these
adverse outcomes without the guidance of immunological assays has proven to be
hazardous and highlights the need for on-going research. Although cyclosporin has
allowed lower maintenance doses of steroids to be used, discontinuation of steroids is
successful in only two-thirds of patients and the increased risk of rejection is
generally thought to be unacceptable (Hricik et al, 1994, 2002; Ratcliffe et al, 1996;
Dunn et al, 1999). These agents are being increasingly replaced by newer drugs that
are more selective and may have fewer side effects. Tacrolimus, mycophenolate
mofetil, sirolimus, and humanised anti-IL-2 receptor monoclonal antibody therapy
undoubtedly improve short-term graft survival, but it is still too early to determine
their impact on long-term outcome.
TOLERANCE INDUCTION STRATEGIES
Transplant tolerance may be defined as the stable long-term engraftment of an organ
in the absence of immunosuppression in a recipient who remains immunocompetent
(Allan et al, 2002). The reduced immune response is specific to the donor antigens
and it appears to be an active process (Kirk et al, 2000). The pioneering work of
Medawar and colleagues (1953), provoked intense study of transplantation tolerance,
as it suggested that long-term graft survival could be attained by inducing specific
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tolerance to donor allo-antigens. This would theoretically reduce the need for high
dose immunosuppression and hence alleviate the problems of drug toxicity.
Many different approaches have been tried to induce tolerance in
experimental models. Historically, recipients of pre-transplant blood transfusion have
shown long-term graft survival in both experimental (Fabre et al, 1972; Wood et al,
1985) and clinical transplantation (Morris et al, 1968; Opelz et al, 1973). The
timing, HLA-match and the systemic administration of antigen all appear to
contribute to donor-specific unresponsiveness after transfusion (Starzl et al, 1996;
Lapchak et al, 2002). However, the introduction of cyclosporin led to the decline in
the use of donor-specific blood transfusion as the benefit to graft survival was less
notable and possible sensitisation of recipients pre-transplant was a concern (Potter et
al, 1991). Successful engraftment of a solid-organ transplant has been achieved
without immunosuppression when accompanied by a bone marrow transplant from
the same donor and this appears to be facilitated by chimerism of donor
haematopoietic cells in the recipient (Sayegh et al, 1991; Helg et al, 1994; Hamawi et
al, 2003). However, the myeloablative treatment needed for this procedure can only
be justified in patients who require bone marrow transplantation for a primary
haematogical disease.
Other methods of inducing unresponsiveness to MHC-mismatched allografts
at the time of transplantation involve lymphocyte depletion which impairs the
primary immune response but allows a gradual repopulation of the lymphoid
compartment. This seems to be associated with the development of
immunnoregulatory mechanisms that maintain tolerance to antigens present at the
time (Kanmaz et al, 2003). In this way, immunological unresponsiveness becomes
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allo-specific, despite the non-specific nature of the initial lymphocyte depletion.
Depletion strategies include total lymphoid irradiation (Strober et al, 1989, 2000;
Reinsmoen et al, 1991) and polyclonal anti-lymphocyte globulin (Burk et al, 1997).
Other more specific strategies include the use of monoclonal antibodies that block
critical ligands in the T cell-APC interaction, such as anti-CD2 (Kaplon et al, 1996;
Bai et al, 2002), anti-CD3 (Nicolls et al, 1993; Burk et al, 1997), and anti-CD4
(Cobbold et al, 1992, 1996; Bushell, 1994; Saitovitch et al, 1995; Hall et al, 2000).
Analogous approaches include the blockade of the costimulatory molecules B7 and
CD28 by the use of CTLA-4 Ig (Pearson et al, 1994), blockade of CD40 ligand by
anti-CD154 (Parker et al, 1995; Xu et al, 2002), or a combination of CD28 and CD40
blockade (Pearson et al, 1996). Alternatively, antibodies directed against leukocyte
function antigen-1 (LFA-1) (Houmant et al, 1996), intercellular adhesion molecule
(ICAM) 1 (Haug et al, 1993), or the IL-2R (Nashan et al, 1997; Vincenti et al, 1998)
also appear to protect against acute rejection.
Although the initial depletion of allo-reactive cells at the time of
transplantation can favour long-term unresponsiveness, inhibition of newly produced
allo-reactive T cells is required to maintain unresponsiveness (Kanmaz et al, 2003).
Other problems associated with tolerance induction protocols include toxicity,
infectious complications and the risk of malignancy. Additionally, many of these
strategies have been successful in animal models, but have been disappointing in
clinical trials. Therefore, the safety and efficacy of these strategies limit their use in
clinical practice and require further study with longer patient follow-up.
Tolerance induction strategies will only be clinically useful if there are means
of monitoring allo-responsiveness. A variety of ways of doing this have been
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described, including assessing direct and indirect T cell alloreactivity by
proliferation, cytokine production, in vivo delayed-type hypersensitivity (DTH), graft
morphology and immunohistochemistry of graft infiltrating cells (Salama et al,
2001). Although some of these assays allow monitoring of the graft-specific immune
response, accurate methods to measure tolerance and their clinical validation are still
lacking. In particular, proliferation assays have been criticised for their lack of
reproducibility and some have shown no correlation with graft outcome. The value of
in vivo DTH assays is uncertain, as only few studies have been performed using this
method. The assessment of graft morphology and detection of staining for cytokine
protein in graft infiltrating cells by immunohistochemistry require invasive
procedures which are not without risk. Cytokine analysis using techniques such as
ELISA, ELISPOT and flow cytometry have all been tried in small studies, but have
not shown a correlation with graft outcome (Reinsmoen et al, 2002).
As immune responsiveness and immune regulation are dynamic processes, it
is likely that more than one method will be required to assess the recipient's immune
status and serial analyses will be required (Salama et al, 2001; Reinsmoen et al,
2002). An approach involving more than one assay will also provide reassurance to
the clinician who is ultimately responsible for the consequences of adjusting
treatment, at least until a single test proves to be reliable and safe. Although
tolerance induction and tailoring of immunosuppresion strategies both require the
guidance by immunological parameters, a reliable functional in vitro assay that gives
quantitative and qualitative assessment of the recipient-donor reactivity is not yet
available.
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MECHANISMS OF ANTIGEN-SPECIFIC TOLERANCE
The mechanisms responsible for transplant tolerance are contentious, but are likely to
be similar to those that have been implicated in other models of peripheral T cell
tolerance. These include clonal anergy or deletion of donor-specific T cells, and the
effects of regulatory T cells that can suppress the function of effector T cells via cell-
cell contact or the production of cytokines such as IL-4, IL-10 or TGF-p.
CLONAL ANERGY
Clonal anergy is the functional inactivation of antigen-specific T cells. It was first
demonstrated by Lamb et al (1983), who showed that T cell clones that were first
exposed to antigen on other T cells in vitro were unable to proliferate normally when
subsequently exposed to antigen on normal APC. The critical effect of anergic T
cells is a failure to proliferate, to act as effector cells or to produce IL-2. In addition,
anergic T cells are not merely passive, but may play an important role as regulatory
cells (Lechler et al, 2001).
Many mechanisms have been proposed to explain the induction of anergy.
Early investigators showed that it may arise following primary antigenic stimulation
in the presence ofAPC that lack appropriate costimulatory signals such as CD28-B7.
This leads to a partial primary response by T cells, followed by a long-lasting state of
unresponsiveness to challenge via the TcR (Jenkins et al, 1987; Quill et al, 1987).
Cell division during the primary response also appears to be important in maintaining
subsequent T cell reactivity, as inhibition of cell cycle progression by anti-IL-2 or
anti-IL-2R (DeSilva et al, 1994), or with the immunosuppressive agent rapamycin
which blocks IL-2R signalling (Powell et al, 1999) can induce T cell anergy, even in
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the presence of costimulation. Although anergy in CD4+ Thl cells can be reversed
by the addition of exogenous IL-2, anergic suppressive CD4+CD25+ cells can be
expanded by IL-2 (Frasca et al, 1997; Witzke et al, 2001).
Anergy may also be induced by peptide antigens that are partial agonists for
the TcR (Lechler et al, 2001). These fail to stimulate primary T cell proliferation,
but induce T cell anergy, even when the APC provides full co-stimulation. Thus, it
appears therefore that any factor which interferes with the overall affinity of the T
cell for its APC during the primary response to antigen may result in anergy.
Humanised non-FcR-binding antibodies against CD3 are promising
immunosuppressive agents that induce anergy by acting as partial agonist ligands of
the TcR and may overcome the adverse effects of conventional monoclonal
antibodies against CD3 used in the treatment of acute rejection (Chau et al, 2001;
Meijer et al, 2001). Non-FcR-binding antibodies may also prime T cells for AICD
upon antigen re-challenge (Yu et al, 2000) and may down-regulate Thl cytokines,
while upregulating Th2 cytokines (Smith et al, 1998).
Cytotoxic T lymphocyte-associated molecule-4 (CTLA-4) is a cell surface
molecule that is expressed on CD4+ and CD8+ T cells after T cell activation (McCoy
et al, 1999; Sansom et al, 2000) and may play a preferential role in the induction of
anergy. CD28 is a T cell surface molecule which delivers a co-stimulatory signal
upon interaction with B7 molecules present on APC (McCoy et al, 1999). Inhibitory
signals delivered by CTLA-4, which has a higher affinity for B7 than CD28, oppose
TcR signalling (Sansom et al, 2000; Kirken et al, 2002) and several mechanisms
have been proposed for this inhibitory effect. CTLA-4 signalling blocks IL-2
production, IL-2R expression and cell cycle progression of activated T cells at a very
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early stage in T cell activation (Krummel et al, 1996; McCoy et al, 1999). In addition
to favouring the development of T cell anergy (Greenwald et al, 2001) CTLA-4 may
also be involved in the function of CD4+CD25+ regulatory T cells (Hara et al, 2001).
In contrast, blockade of CTLA-4 leads to enhanced T cell proliferation. This is most
clearly demonstrated in CTLA-4 knockout mice that develop fatal
lymphoproliferative disease (Waterhouse et al, 1995).
Other newly identified costimulation molecules belonging to the CD28-B7
family may also be invloved in regulating T cell responses. PD1, which resembles
CD28 and CTLA-4, is expressed on activated T, B and myeloid cells and has two
recognised ligands called PDL-1 and PDL-2 (Bernard et al, 2002). The PD-1
pathway is also an inhibitory pathway that acts synergistically with CTLA-4 to help
switch off T cell responses against non-self antigens by inducing expression in DC
upon their activation (Bernard et al, 2002). Therefore, it appears that strategies
which promote CTLA-4 expression while down-regulating CD28 costimulation may
be clinically desirable.
CLONAL DELETION
Deletion of antigen-reactive T cells in the thymus has been shown to be the most
important mechanism for the induction of tolerance to self-antigens during the
development of the immune system (Kappler et al, 1987). Clonal deletion may also
play a role in peripheral tolerance, which occurs after mature T lymphocytes have
emigrated from the thymus. T cell death via apoptosis is generally considered to be
the mechanism of clonal deletion and two mechanisms have been described -
activation-induced cell death (AICD) and passive cell death (PCD) (Li et al, 2001).
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AICD refers to the susceptibility of activated T cells to undergo apoptosis when high
levels of IL-2 production induce expression of the death receptors, Fas and FasL, on
activated T cells. PCD occurs when activated effector cells are deprived of growth
factors such as IL-2. Li et al (2001) have shown that IL-2 dependent AICD plays a
critical role in the development of allograft tolerance following islet cell
transplantation and similar findings were reported by another group following
murine cardiac allograft transplantation (Dai et al, 1998).
ACTIVE REGULATION
CD4+ T cells are central to the development of both allograft rejection and the
induction of tolerance (Nickerson et al, 1994, 1997; Field et al, 1997; Zelenika et al,
2001; Waldmann et al, 2001). Infectious tolerance was one of the first indications
that CD4+ T cells can be induced to have a regulatory function. Waldmann et al
demonstrated this phenomenon, whereby regulatory T cells that developed after anti-
CD4 antibody therapy can enable other T cells to become tolerant and to have
regulatory function (Qin et al, 1993; Waldmann et al, 2001). Anti-CD4 is not the
only target immunosuppressive therapy that may result in infectious tolerance.
Blockade of CD28-B7 by CTLA-4 (Onodera et al, 1997) and anti-CD40L combined
with anti-CD8 (Honey et al, 1999) can also induce this state.
Mosmann et al (1986) first demonstrated that CD4+ T cells may produce
distinct profiles of cytokines and suggested that there may be different functional
subsets. The two T helper cell subsets, Thl and Th2, are derived from a common
ThO precursor and the microenvironment influences whether ThO cells will polarise
into a Thl or Th2 cell. The principal early event in Thl differentiation is the
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production of IL-12 by macrophages and dendritic cells in response to inflammation
or pathogen products (Trinchieri et al, 1995). Thl cells produce IL-2 and IFN-y
which promote cellular cytotoxicity and delayed-type hypersensitivity reactions. ThO
cells differentiate into Th2 cells in the presence of IL-4 and produce IL-4, IL-6, IL-9,
IL-10 and IL-13 and support humoral immune responses. Thl and Th2 cytokines are
reciprocally antagonistic since IFN-y inhibits the proliferation of Th2 cells, while IL-
10 inhibits IL-12 production and the differentiation of Thl cells (Coffman et al,
1997).
It has become apparent that other CD4+ T-cell subsets which do not conform
to a classical type 1 and 2 cytokine profile exist and may play an integral role in the
regulation of many aspects of T cell function. In particular, a number of different
regulatory T cells (T-reg) have been described in different forms of tolerance,
including oral tolerance (Weiner et al, 1994), autoimmunity (Sakaguchi et al, 2000),
inflammatory bowel disease (Groux et al, 1997, 1999), and transplantation (Hall et
al, 1985; Qin et al, 1993; Zhai et al, 1999; Waldmann et al, 1998, 2000). Th3 cells
were first identified by Weiner et al (1994) in studies using oral administration of
protein antigens to suppress autoimmune disease. These inhibit other T cells by
secreting TGF-p. A further subset of TrI cells has been described which is
generated in vitro in the presence of IL-10 and produces IL-10 preferentially (Groux
et al, 1997). These inhibit antigen-specific T cell responses via inhibition of IL-2
and IL-2R expression (Groux et al, 1996) and by the suppression of APC function
(Groux et al, 1998). Much attention has focused recently on regulatory CD4+ T cells
which express high levels of CD25. These appear to arise spontaneously in the
thymus and are exported to the periphery where they function as potent suppressor
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cells in preventing T cell responses to self antigens (Shevach et al, 2000). The
precise mechanisms underlying their suppressor activity is controversial, but it
requires stimulation via the TcR and a variety of factors have been suggested,
including IL-10, TGF-P (Dieckmann et al, 2002; Jonuleit et al, 2002) and CTLA-4
(Kingsley et al, 2002). Cell-cell contact seems to be essential and the suppressed cell
shows inhibition of IL-2 and IFN-y gene transcription. The suppressive effect can be
overcome by the addition of exogenous IL-2 (Thornton et al, 2000). In addition to
spontaneously arising regulatory CD4+CD25+ T cells, it may also be possible to steer
an uncommitted T cell toward regulatory function by repetitive stimulation with
immature dendritic cells, or by the presence of regulatory cytokines such as IL-10
and TGF-P (Garin et al, 2003).
T-reg cells may affect the functional activity of other T cells directly, or
indirectly by modifying the function of APC. T-reg cells can inhibit proliferation
and cytokine production, eliminate effector cells by promoting apoptosis, facilitate
the induction of anergy, or convert effector T cells to a regulatory phenotype (Wood
et al, 2003). There is also evidence from in vitro studies that T-reg cells can down-
regulate the expression of co-stimulatory molecules, such as CD80 and CD86,
thereby rendering APC less able to trigger T cell activation (Cederbom et al, 2000;
Taams et al, 2000). T-reg cells have also been shown to prevent graft rejection by
impairing the function of CD8+ T cells (van Maurik et al, 2002; Lin et al, 2002).
Active regulation is now accepted to be important in the induction and maintenance
of specific immune unresponsiveness to alloantigens following both organ (Hara et
al, 2001; Kingsley et al, 2001) and bone marrow transplant (Hoffman et al, 2002) in
vivo. Furthermore, a balance between regulation and deletion of responder T cells
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has been shown to be an effective strategy in controlling responsiveness after
transplantation (Wood et al, 2001; Wells et al, 2001).
The mechanisms of action of Treg remain to be established. It has been
widely proposed that a shift towards a Th2 cytokine profile might support allograft
tolerance (Sayegh et al, 1995; Chen et al, 1996a; Onodera et al, 1997), while a
predominance of a Thl profile may lead to allograft rejection (Mottram et al, 1995;
McLean et al, 1997; D'Elios et al, 1997). Infectious tolerance after blockade of CD4
may be dependent on Th2 cytokines, particularly IL-4, in vivo (Davies et al, 1996;
Onodera et al, 1997; Bushell et al, 1999), and on IL-10 and TGF-P in vitro
(Dieckmann et al, 2002). These regulatory CD4+ T cells can also mediate linked
suppression, whereby T cells specific for an unrelated third party antigen can be
tolerised if both tolerising and third party antigens are presented together on the same
graft (Davies et al, 1996; Chen et al, 1996b). Early studies showed that high IL-10
production was associated with skin, cardiac and islet graft acceptance (Hancock et
al, 1993) and with the induction of neonatal and adult tolerance to foreign antigens
(Bacchetta et al, 1994). Many tolerance induction regimens have also shown a
predominance of Th2 cytokines (Sayegh et al, 1995; Zeng et al, 1996; Field et al,
1997). Further evidence for a role of Th2 cytokines in graft acceptance has come
from studies in liver transplantation, where high levels of donor-specific IL-4 and IL-
10 have been found to be strongly associated with stable liver allograft function
independent of the level of immunosuppression, while patients who develop acute
rejection produce high levels of IFN-y (Chung et al, 1998; Minguela et al, 1999).
These findings may help explain why the liver appears to be less immunogenic than
the kidney following allo-transplantation. However, other investigators have not
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supported the hypothesis of a Th2 bias in allograft tolerance, as both Thl and Th2
cytokines may be expressed within the graft during acute rejection and tolerance can
be observed in the absence of Th2 cytokines (Dallman et al, 1995; Picotti et al, 1997;
Kuzendorf et al, 1998).
Therefore, it is unclear how Th2 cells contribute to tolerance, or if they
simply arise as a result of the tolerant state. Disappointingly, attempts to induce
tolerance either by enhancing the development of Th2 cells in vivo (Chan et al, 1995;
VanBuskirk et al, 1996; Picotti et al, 1996), or by the systemic administration of IL-4
and/or IL-10 (Vossen et al, 1995; Qian et al, 1996) have failed to prolong graft
survival. The conflicting evidence for the relative contributions of Thl and Th2
cytokines in graft acceptance and rejection may reflect variations in inductive
strategies, the organ involved, and whether the graft was immediately vascularised or
not. Furthermore, many of the early studies relating cytokine production following
transplantation have been based on the expression of cytokine genes in the grafts, or
by identifying graft infiltrating cells that stain for cytokine protein by
immunohistochemistry which do not always reflect antigen-specficity (Picotti et al,
1997).
Graft acceptance has also been found in association with donor-specific IL-10
and TGF-P production. TGF-P is a cytokine with immunoregulatory properties and
can control the differentiation, proliferation and state of activation of several immune
cells (Letterio et al, 1998). Induction of allo-specific tolerance by transfusion of
donor cells has been shown to be associated with high levels of TGF-P mRNA and
protein, and it can be reversed by the administration of anti-TGF-P monoclonal
antibody (Josien et al, 1998). Furthermore, apoptosis of allo-reactive cells can induce
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production of IL-10 and TGF-p (Gao et al, 1998). Although cytokines are important
in immunoregulation, it is likely that the pathway to allograft tolerance involves
more than one of the mechanisms described above. This is evidenced by the findings
that clonal deletion and immune deviation may occur simultaneously in neonatal
tolerance (Matriano et al, 1994; Donckier et al, 1995), as well as in other models of
tolerance (Gao et al, 1998), and that otherwise anergic T cells may act as regulatory
cells (Lechler et al, 2001).
MICROCHIMERISM
Microchimerism is the persistence of donor-derived haematopoietic cells,
particularly dendritic cells, in recipient tissues many years after transplantation
(Starzl et al, 1992, 1993; Larsen et al, 1990; Burlingham et al, 1996). Numerous
reports have supported the idea that microchimerism is the mechanism of tolerance
induced by donor-specific blood transfusion (Flye et al, 1995) or allogeneic bone
marrow transplantation (Dey et al, 1998; Butcher et al, 1999; Flamawi et al, 2003).
Early development and long persistence of microchimerism has also been suggested
as one reason why liver allografts are relatively resistant to rejection compared with
other organs (Starzl et al, 1992; Lu, 1995). However, the exact role of
microchimerism remains controversial and some workers have found no evidence of
microchimerism in patients who show operational tolerance (Bushell et al, 1995;
Fuchinoue et al, 2002). In addition, there is debate over the most appropriate
methods of detection, the anatomical sites in which it is found (Noris et al, 2001), as
well as its clinical relevance (Strober et al, 2000). Although the persistence of allo-
antigens appears to be essential for most of the other mechanisms implicated in the
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development of tolerance (Khan et al, 1996), it may be the graft itself, and not
microchimerism, that is crucial for the maintenance of tolerance in vivo (Hamano et
al, 1996; Karim et al, 2002; Wood et al, 2003).
DSH
Donor-specific hyporesponsiveness was first described by Amos and Bach, when
they demonstrated that lymphocytes from certain recipients of allogeneic kidneys
showed uni-directional unresponsiveness to donor cells in mixed lymphocyte
culture (Amos et al, 1968). Later, Garovoy et al (1973) showed that all recipients
who were 8 to 12 years post-transplant were non-responsive to donor stimulation
and Thomas et al (1977) demonstrated a trend toward lower donor-specific
responses in patients 8 to 12 years after transplant compared with those 2 to 5 years
post-transplant. However, these early studies were hampered by the fact that HLA
antigens, particularly Class II HLA antigens, were poorly defined at that time, and
by the use of patients' sera in the culture medium. Although DSH may not
necessarily signify true antigen-specific tolerance, as most patients are
immunosuppressed and some patients who show DSH develop acute rejection
following withdrawal of immunosuppression, it does represent a reduced reactivity
to donor cells. As it is unethical to discontinue immunosuppression for the purpose
of immunological study, DSH appears to be the closest marker of tolerance in
clinical transplantation. As DSH has also been described in patients who maintain
their grafts without immunosuppressive therapy, it seems likely that DSH reflects
antigen-specific tolerance and not a complication of immunosuppression.
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More recently, prospective studies have been performed to assess how DSH
develops after transplantation. In cadaveric recipients followed for up to 4 years, the
reported incidence ofDSH ranged widely from 25-74% (Bas et al, 1992; Reinsmoen
et al, 1993; Ghobrial et al, 1994; Creemers et al, 1997; Kerman et al, 1997). There
are many factors which may explain this large variation in incidence, including the
use of anti-lymphocyte globulin as a part of a tolerance induction regimen (Bas et
al, 1992), the use of homozygous typing cells rather than the original donor cells in
MLR (Reinsmoen et al, 1990, 1993) and the application of different methods to
define DSH. Among living-related recipients, the reported incidence of DSH within
the first two years post-transplant ranges from 95-100% for HLA-identical
recipients and 31-47% in HLA-haploidentical grafts (Fletchner et al, 1984; Kahan et
al, 1989; Kerman et al 1997).
The clinical relevance of DSH is that it has been shown to correlate with a
favourable long-term graft outcome. Patients who show DSH have a lower
incidence of acute rejection after the first three months post-transplant (Reinsmoen
et al, 1990, 1993, 1994; Kerman, 1997; Creemers, 1997; Ghobrial, 1994) and a
better 3-year (Reinsmoen et al, 1993) and 10-year (Kerman, 1997) graft survival.
However, it should be noted that Steinmann et al (1994) showed no correlation
between DSH and graft outcome, despite using a number of techniques to assess
alloresponsiveness. Although DSH has also been found to be associated with a
lower risk of chronic rejection in renal, heart and lung transplant recipients
(Reinsmoen et al, 1994), other reports have shown that DSH may still occur in some
patients with biopsy-proven chronic rejection (Reinsmoen et al, 1993; Bohmig et al,
2000). Therefore the detection of DSH may help to identify patients at low risk of
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adverse immunological events, but its presence is not exclusive to patients with
good graft outcome.
METHODS OF DETECTING DSH
Cellular assays have been developed to test for various effector and cytotoxic
functions of T cells and have been used to assess the immune profile of solid organ
recipients. One goal of these studies has been to determine if post-transplant changes
in donor-specific cellular response could predict good versus poor graft outcome,
which would allow individualisation of immunosuppression (Reinsmoen et al, 2002).
Many techniques have been used to identify patients who show donor-specific
hyporesponsiveness towards donor antigens. These include the mixed lymphocyte
reaction, cell-mediated lympholysis, limited dilution assays, and most recently, in-
vivo delayed-type hypersensitivity.
The mixed lymphocyte reaction (MLR), which measures the proliferative
activity of recipient T cells against donor Class II MHC antigens, was the first
technique used to demonstrate DSH (Amos and Bach, 1968). These investigators
postulated that non-reactivity was caused by the absence of clones that can react to
the allo-grafted HLA antigens and even at this early stage, Bach et al (1972)
speculated that it might be possible to withdraw immunosuppression in recipients
showing DSH. Since then, the MLR has been used widely to demonstrate antigen-
specific hyporeactivity in vitro following renal transplantation (Charpentier, 1982;
Fletchner et al, 1984; Kahan et al, 1989; Reinsmoen, 1990, 1991, 1993, 1994; Bas et
al, 1992, 1993; Ghobrial et al, 1994; Fugiwara, 1994; Iniotaki-Theodoraki et al,
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1995; Kim et al, 1996; Jackson et al, 1997; Kerman et al, 1997; Creemers et al, 1997;
Salomao et al, 1998; Ishido et al, 1999; Bohmig et al, 2000). However, as noted
above, considerable variability has been reported and the reliability of the assay is
affected by a number of factors, including the source of the serum used in the culture
medium, the nature and number of the stimulator cells, as well as the fact that
patients have been selected according to widely varying criteria.
Another way that has been used to demonstrate DSH is the cell-mediated
lympholysis (CML) assay which measures recipient cytotoxic T cell activity, mainly
against donor Class I MHC antigens (Thomas et al, 1977; Goulmy et al, 1981;
Pfeffer et al, 1983; Ono et al, 1983; Cohen et al, 1985; Fletchner et al, 1986;
Wrammer et al, 1987; Fugiwara et al, 1994). The largest of such studies concluded
that the correlation between CML responder status and graft outcome was of limited
prognostic value (Goulmy et al, 1981). Although Fletchner et al (1986) reported a
good correlation between MLR and CML assays, this was disputed by Fugiwara et al
(1994) who found that persistent donor-specific responsiveness could often be
detected by MLR, when there appeared to be unresponsiveness in the CML assay. As
a result of these conflicting data, lack of correlation with graft outcome, and the fact
that CML mainly measures Class I responses compared with Class II responses in
MLR, the CML assay is now rarely used to assess donor-specific responsiveness.
Limited dilution assays (LDA) measure the frequency of precursors for
cytotoxic T cells (pCTL) or IL-2 secreting peripheral blood T cells (pHTL) in the
recipient following stimulation with donor cells and has also been used widely to
demonstrate DSH (Bishop et al, 1989; Grailer et al, 1991; Hadley et al, 1992; Mason
et al, 1996; Beik et al, 1997; Hornick et al, 1997; Van Besouw et al, 2000).
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Although pCTL frequencies were reported to be useful in identifying kidney
recipients in whom immunosuppression could be reduced (Beik et al, 1997; Van
Besouw et al, 2000), others have reported low precursor frequencies may occur in a
substantial number of recipients with chronic rejection (Mason et al, 1996; Hornick
et al, 1998 and Baker et al, 2001). These discordant results may be the result of the
relatively small number of recipients tested, different immunosuppressive regimens,
varying LDA methods or the use of a single time point to define hyporeactivity
rather than kinetic analysis of responder status (Reinsmoen, 2002). Additionally,
pCTL is a measure of Class I responses and this assay is difficult to perform.
Since my work was carried out, in-vivo delayed-type hypersensitivity (DTH)
assays have been used to assess the immune status of allograft recipients (Van
Buskirk et al, 2000; Geissler et al, 2001). This method involves the injection of
recipient peripheral blood mononuclear cells, together with donor antigen into the
footpads or pinnae of naive mice. If the recipient had been sensitised to donor
antigens, a DTH-like swelling develops in the mouse skin due to recognition of the
donor antigen and resultant inflammation. Geissler et al (2001) tested liver
transplant recipients who had stopped all immunosuppression and reported that the
DTH assay was better than the conventional CML and MLR assays for detecting
donor antigen-linked suppression and suggested that the DTH assay may be a
suitable method of assessing tolerance in clinical trials.
To date, only a few studies have measured T cell reactivity before and after
the reduction of immunosuppression (Goulmy et al, 1991; Mazariegos et al, 1995;
Beik et al, 1997; Creemers et al, 1998; Van Besouw et al, 2000, 2002), with one
group showing that there was no rebound effect of increasing donor-specific
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reactivity up to two years after tapering of immunosuppression (Van Besouw et al,
2002). However, only one centre has used immunoassays prospectively to reduce
immunosuppression in patients who demonstrate DSH, but this was only attempted
in living-related allograft recipients (Fletchner et al, 1984; Kahan et al, 1989;
Kerman et al, 1997). MLR-defined DSH was detected in all HLA-identical
recipients and in 47% of the haplo-identical recipients. These patients were selected
for steroid withdrawal, but the five-year (Kahan et al, 1989) and the ten-year follow-
up results (Kerman et al, 1997) showed variable success on cyclosporin
monotherapy, with both acute rejection episodes and graft losses occurring after
steroid withdrawal. Hence, there remains no sensitive or specific in vitro tests that
reliably predict the success or failure of steroid withdrawal.
All in vitro assays have been subject to criticism and the method used to
assess allo-reactivity appears to influence the percentage of recipients identified as
being hyporesponsive. The combined literature indicates that DSH is identified in
70% of recipients by the CML assay and in only 30% of recipients by MLR
(Reinsmoen, 2002). A method that underestimates the incidence of DSH is likely to
be better than a method that over-estimates it, as the consequences of a false positive
test could result in allograft rejection or graft loss. In my study I have used the MLR
to assess proliferative responses, as MLR reactivity reflects MHC Class II disparity
which has the biggest influence on acute rejection in clinical practice. In addition,
MLR-defined DSH correlates with graft outcome, and this is the only technique
which has been used to tailor immunosuppression.
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DEFINITION OF DSH
As with the techniques used to detect DSH, there is also no consensus on how it
should be defined and many investigators do not substantiate in any detail the
definition chosen in their studies. In most cases, DSH has been defined by comparing
pre-transplant proliferative responses against donor and third party (ThP) control
cells, with the equivalent responses found after transplantation. Here, I will discuss
only those definitions that have been applied to MLR-based assays, as this was the
method I used to detect DSH.
Firstly, DSH has been defined using the relative response index (RRI), which
measures the recipient's proliferative response to donor cells in proportion to that
found against third party cells. It is calculated by the following formula:
RRI (%) = cpm (Recipient + Donor) — (Recipient + Recipient) x 100
cpm (Recipient + Th P) - (Recipient + Recipient)
where (Recipient + Recipient) represents the background response obtained using
autologous stimulators. Some investigators have defined DSH as a two-thirds
reduction in the RRI post-transplant compared with the pre-transplant RRI
(Reinsmoen et al, 1990, 1993, 1994; Bas et al, 1992), while others have defined DSH
as an RRI of < 20% at any time after transplantation (Colombe et al, 1989; Ghobrial,
1994; Kim, 1996; Salomao et al, 1998; Ishido, 1999). One group reported that a RRI
of < 20 ± 8% correlated with good graft outcome after eight years post-transplant
(Salomao et al, 1998).
A second way of defining DSH has been to compare the stimulation indices
(SI) obtained with donor stimulation and third party stimulation. The SI are
calculated by the following formulae:
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SI = cpm (Recipient + Donor) SI (Th P) = cpm (Recipient + Th P)
cpm (Recipient + Recipient) cpm (Recipient + Recipient)
Again, multiple cut-off values have been used to define DSH by this method. In
some cases, patients who displayed a donor-specific SI < 6.5 and a third party SI >
6.5 were considered to show DSH (Fletchner et al, 1984; Kahan et al, 1989), whereas
Kerman et al (1997), working in the same centre, used a donor-specific SI < 10 and a
third party SI > 10 to define DSH. In another centre, DSH was defined as a donor-
specific SI < 6 with a third party SI > 6, and this correlated with good graft survival
(Salomao et al, 1998). I did not select this method to define DSH as the definition of
a meaningful SI appeared to be arbitrary.
Thirdly, DSH has been defined by the donor-specific reactivity (DSR), which
calculates donor-specific proliferation as a proportion of the third party response
obtained when a panel of three stimulator cells are used as the third party control
(Creemers et al, 1997). It is calculated by the following formula:
DSR = (Recipient + Donor)
0.33 x [Recipient + (Panel of 3)]
As this method does not take into account autologous background proliferation,
which is an important factor in assessing the donor-specific proliferative response, it
was not considered appropriate for my study.
Lastly, DSH has been defined as the "relative specific reactivity", which
represents donor-specific proliferation as a proportion of the recipient's mean
proliferative response against a panel of 5 individual third party control cells at each
time-point post-transplant compared with the respective pre-transplant responses
(Bohmig et al, 2000). It can be calculated by the following formulae:
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Donor-specific reactivity (%) = cpm ( Recipient + Donor) (post-Tx) x 100
cpm (Recipient + Donor) (pre-Tx)
General reactivity (%) = cpm 0.2 x [(Recipient + (Panel of 5)1 (post-Tx) x 100
cpm 0.2 x [(Recipient + (Panel of 5)] (pre-Tx)
Relative specific reactivity (%) = Donor-specific reactivity x 100
General reactivity
This method was reported to minimise the effects of uraemia, infection or changes in
immunosuppressive regimen and to give a more accurate representation of donor-
specific T cell alloresponses as it took into account pre-transplant donor-specific and
third party responses at each time point post-transplant. However, I did not use this
method to define DSH, as pre-transplant MLR studies could not be performed on the
retrospective cohort in my study.
The fact that many overlapping, but distinct and often arbitrary methods have
been used to define DSH has undoubtedly contributed to the discrepancies in the
predictive value of the phenomenon. I chose to define DSH using the RRI, as it the
most widely used method, takes into account background proliferative responses, and
allows for single time-point analysis which was necessary in the retrospective cohort
ofmy study.
I also assessed donor-specific cytokine production, as MLR-defined DSH on
its own, has not proven to be sufficient in guiding reduction of immunosuppression.
The underlying mechanism of DSH remains unknown, but as I have discussed above,
it may involve active immune regulation. The possibility that DSH is associated with
the production of inhibitory cytokines in response to donor stimulation has only been
investigated in case reports of living-related recipients who showed DSH while
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maintained without immunosuppression (Kusaka et al, 1995; Christensen et al, 1998;
Ishido et al, 1999). These reports suggest that DSH may be associated with a Th2
cytokine profile. As most transplant patients are maintained on immunosuppression,
it would be important to determine whether the assessment of donor-specific
cytokine production is of value under these circumstances.
SUMMARY AND AIMS
Transplantation has become the preferred mode of renal replacement therapy for
most patients with end-staged renal failure. However, the induction of specific
immunological tolerance is not yet possible and immunosuppressive therapy remains
the mainstay of treatment. New immunosuppressive agents have further improved
short-term allograft survival, but some have been in clinical use for too short a period
to determine their effect on long-term graft survival. Unfortunately, some of these
agents also increase the risk of infection, malignancy and heart disease.
Theorectically, minimisation or elimination of the side effects of immunosuppressive
drugs should be possible by substitution of toxic drugs, or by the withdrawal of a
specific drug in stable patients. However, clinical trials have shown varied outcomes
of doing this and until there is a reliable immunological method for selecting
appropriate patients for reduction of immunosuppression, it is likely that many will
receive more immunosuppression than is actually needed to protect the graft.
The study of allograft tolerance is complicated by the use of
immunosuppression in clinical transplantation and true antigen-specific tolerance has
been described only in case reports and in small series of patients who have
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discontinued immunosuppression. DSH appears to represent a tolerance-like state in
immunosuppressed individuals which may be associated with better long-term graft
survival due to a reduced incidence of acute and chronic rejection. Although the
mechanism of DSH remains unknown, it may involve one or more of the
mechanisms implicated in other forms of peripheral T cell tolerance, including clonal
anergy, clonal deletion, and cytokines produced by regulatory T cells. Previous
investigators have used a number of different techniques to demonstrate DSH, but
the use ofmultiple different definitions to define DSH makes it difficult to interpret
many of these studies.
The aim ofmy study was to determine whether good graft outcome correlated
with the presence of DSH and the selective production of inhibitory cytokines that
have been associated with the induction of antigen-specific tolerance. DSH was
detected by MLR and cytokines were analysed by ELISA and RT-PCR. The
standardisation of these techniques is described in Chapter 2. The results of a group
of long-term surviving cadaveric recipients with varied allograft outcome, referred to
as the Cadaveric Cohort, are described in Chapter 3, while a group of living-related
recipients, the Living-related Cohort, is described in Chapter 4. A small group of
cadaveric recipients on low-dose immunosuppression as a result of solid-organ
malignancy, the Malignancy Cohort is discussed in Chapter 5. Chapter 6 then
outlines the evolution of DSH and sequential cytokine analysis in a group of
cadaveric and living-related recipients during the first year post-transplant, the
Prospective Cohort. Finally, Chapter 7 is a general discussion of my findings in
relation to previous work and highlights areas of potential future study.
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CHAPTER 2: MATERIALS AND METHODS
STUDY DESIGN
This study was performed in two arms. The retrospective study examined a cohort of
cadaveric and living related recipients with long-term functioning renal allografts,
and provided a foundation for interpretation of the prospective study. The
retrospective arm of the study was designed to determine whether good allograft
outcome in long-term graft survivors was associated with donor-specific
hyporesponsiveness and a specific pattern of cytokine production. The prospective
study was carried out to determine whether patients who developed DSH within the
first year post-transplantation had a similar cytokine profile to that of long-term
survivors who show DSH. The overall aim was to test whether cytokines might be
of predictive value in tailoring immunosuppression.
Approval was obtained from the local Ethical Committee before patients
were recruited. The proposal outlined the main aims of the project, materials and
methods (including the use of radioactive substances and information regarding
certification for laboratory use and disposal), procedures involving patients and
volunteers, safety and funding. Patients were asked to participate in the study at a
routine clinic visit. An information sheet about the project, which was also approved
by the Ethical Committee, was given to all patients and 30ml blood was then
obtained after informed consent.
33
Retrospective Study
Patients considered for this study had to be first renal allograft recipients, excluding
all those who were pregnant and unable to give informed consent. A database search
was performed to identify suitable patients. Recipient details, including date of birth,
date of transplant, HLA type, panel reactive antibody (PRA) status, baseline and
current immunosuppressive regimes, and level of graft function were obtained from
computer and casenote records. The PRA represents the recipient's level of
sensitisation against a panel of known Class I and II HLA antigens prior to
transplantation and was measured routinely at three-monthly intervals while on the
transplant waiting list.
An extensive casenote search was then carried out to verify acute and chronic
rejection history based on histopathology reports. As there was no reliable record of
blood transfusion prior to transplantation in the casenotes, each participant was asked
about previous blood transfusions at the time of giving consent. In all cases, these
had been given as treatment for anaemia and not as part of a planned pre-transplant
blood transfusion programme. T-cell complement dependent cytotoxicity cross
match was also negative prior to transplantation in all patients.
Donor information was obtained from the Tissue Typing Laboratory at
Glasgow Royal Infirmary. The tissue type and degree of HLA-mismatch to the
recipient were obtained from laboratory records for all patients. Donor cells were
extracted from spleen following organ retrieval, cryopreserved and the number of
cryopreserved cells recorded. Patients identified from the database search were
considered for the study only if adequate donor material was available. Patients were
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then entered into the study in one of three cohorts based on the criteria described
below. Clinical details ofpatients are given in the appropriate chapters.
CADAVERIC COHORT
All patients were first renal allograft recipients with a functioning transplant for more
than five years. Two patient groups were defined to determine whether the presence
of donor-specific hyporesponsiveness correlated with graft outcome.
GROUP A
Patients in this group had a good allograft outcome, as shown by no acute rejection
beyond the first three months post-transplant and good allograft function with a
serum creatinine < 140 mol/l. There was no history of chronic rejection.
GROUP B
Patients in this group had poor allograft outcome with either late, multiple or steroid-
resistant acute rejection, or biopsy-proven chronic rejection. Their level of graft
function was not defined biochemically.
LIVING-RELATED COHORT
This cohort comprised recipients with a functioning renal allograft from a living-
related donor. The number of patients with a functioning graft for more than five
years whose donor was available to provide cells was small. Therefore, patients with
a functioning primary allograft for more than three years were considered. They
were analysed in the same outcome groups defined above in the cadaveric cohort.
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Once consent was obtained from the recipient, the organ donors were contacted by
telephone or letter to request their participation. Clinical information on each
recipient and donor was obtained from computer and casenote records. Details of
HLA-typing and level of sensitisation were obtained from the Tissue Typing
Laboratory.
MALIGNANCY COHORT
The final cohort included patients who had developed a histologically confirmed,
solid organ malignancy post-transplant. These patients were studied as they have
maintained their grafts despite minimal immunosuppression. All were first graft
recipients and had a functioning allograft for more than five years, but the level of
graft function and rejection history were not used as selection criteria. The type of
malignancy, organ involvement and time of diagnosis post-transplantation are
described in Chapter 5.
Prospective Study
Recipients of first cadaveric or live-donor renal allografts were eligible for this arm
of the study. Again, the only exclusion criteria were pregnancy and inability to give
informed consent. The follow-up period was one year and blood was obtained from
each patient immediately before transplantation, and then at 3 months, 6 months and
12 months post-transplantation. Donor cells were cryoperserved in the Tissue
Typing laboratory at the time of organ retrieval and stored. Recipient information
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including the age, tissue type, and previous level of sensitisation was obtained from
computer and casenote records. The clinical course of each patient was followed,
with a record kept of the immunosuppressive regime, level of graft function,
rejection history and graft loss. In order to reduce variability, all the assays of
cellular function and cytokine production were performed in parallel on completion
of the follow-up period when all samples had been collected. Samples of some
patients who lost their grafts before the end of the study period were also analysed.
CELL ISOLATION
Recipient (Responder) Cells
In the Retrospective Arm of the study, blood was obtained prior to the morning dose
of cyclosporin or tacrolimus at a routine clinic visit. In the Prospective Arm of the
study, blood was obtained immediately before transplantation and thereafter at
routine clinic visits at 3, 6 and 12 months post-transplant. Peripheral blood
mononuclear cells (PBMC) were isolated from 30 ml blood in EDTA using standard
density gradient centrifugation (Lymphoprep, Nycomed, Norway). 10 ml whole
blood was layered carefully onto 15 ml Lymphoprep in a 50 ml centrifuge tube. This
was centrifuged for 30 minutes at 1500 rpm and then the cell layer was harvested,
washed twice in RPMI 1640 (GibcoBRL, Paisley, UK) and the viability and cell
count assessed by phase contrast microscopy. The cells were suspended in foetal calf
serum supplemented with 10% DMSO, gradually frozen to -70°C and cryopreserved
in liquid nitrogen until ready for use.
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Third party stimulator cells
As it was not feasible to obtain a single third party control with the same degree of
HLA-mismatch as the recipient-donor pair for all of the patients in this study, a pool
of stimulator cells from 5 unrelated normal volunteers was used. The tissue types of
the members of the pool, representing seven different HLA-DR types (DR 1, 2, 3, 4,
6, 7, 8), are shown in Table 2.1. Cells from each pool member were obtained using
the method described above and cryopreserved individually. To create the third party
pool control, one aliquot from each member was thawed and equal numbers of each
were mixed. All allograft recipients in this study were tested against the same pool.
Table 2.1: HLA-types of the pool members used in the MLR for
third party selection.
POOL MEMBER HLA - A HLA - B HLA-DR
1 1,8 27 3,2/15
2 2,3 13,27 1,4
3 1,2 5, 8 3/17, 8
4 1,11 8, 17 4, 6/13
5 1 57 7
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Donor splenocytes
Donor spleen tissue was obtained at the time of organ retrieval and the cells were
extracted and cryopreserved by the Tissue Typing Laboratory at Glasgow Royal
Infirmary. The cells were transported in liquid nitrogen to the Western Infirmary for
immediate storage in liquid nitrogen.
MIXED LYMPHOCYTE REACTION
Standardisation of Protocol
The MLR method described below was devised on the basis of optimal conditions
which were established by the following experimentation. First, foetal calf serum
(FCS) was compared with human AB serum (from untransfused male donors) as a
supplement in the culture medium (Figure 2.1). Secondly, a range of responder and
stimulator cell numbers was tested. The highest donor-specific proliferation was
achieved with a cell number of 2 x 105 cells/well (Figure 2.2a) and the highest
proliferation to mitogenic stimulation was achieved with a responder cell number of
lx 105 cells/well (Figure 2.2b). Lastly, a time course study was performed to
determine the optimal duration of culture. Peak proliferation following stimulation
with lmg/ml PHA (Murex Diagnostics, Temple Hill, Dartford, UK) was consistently

















Figure 2.1: Comparison of MLR responses in the presence of FCS or human
AB serum. Results shown are mean 'H-TdR incorporation + 1 s.d. for
triplicate cultures of normal volunteer responder cells stimulated for 6 days with
cells from an unrelated volunteer (R/S) or for 3 days with lmg/ml PHA in
medium containing 10% FCS or AB serum. BGD represents the background
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Figure 2.2: Dependence of MLR responses on donor cell numbers. Results shown
are mean H-TdR incorporation + 1 s.d. of different numbers of normal responder
cells cultured in the presence of similar number of stimulator cells from an unrelated
volunteer (R/S) for 6 days (a) or lmg/ml PHA (b). BGD represents the background






























Figure 2.3: Time course study of mixed lymphocyte responses. Results shown are
mean 3H-TdR incorporation + 1 s.d. of normal responder cells (2 xl0&/ml) cultured in
the presence of lmg/ml PHA (a) or stimulator cells (2 xl06/ml) from an unrelated
volunteer (R/S) for 6 days (b). BGD represents the background responses obtained
from responder cell stimulated with autologous stimulators.
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MLR METHOD
Donor and recipient ceils were thawed rapidly, washed in RPMI 1640 (GibcoBRL,
Paisley, UK) supplemented with 50% human AB serum (Quest Biomedical, Knowle,
West Midlands, UK) and assessed for viability by phase-contrast microscopy.
Donor, third party and autologous stimulator cells were treated with
50pg/107cells/ml mitomycin c (Sigma, Poole, Dorset, UK) for 45 minutes at 37°C,
washed three times, and brought to a working concentration of 2 x 106 cells/ml.
Equal numbers of responder and mitomycin c treated stimulator cells at 2 x 106
cells/ml were cultured in RPMI 1640 supplemented with 10% human male AB
serum, 2mM L-glutamine (GibcoBRL), 100pg/ml penicillin (GibcoBRL) and
lOOpg/ml streptomycin (GibcoBRL) in 96 well round-bottomed tissue culture plates
(Corning Costar, High Wycombe, Bucks, UK) for 6 days at 37°C in a humidified
atmosphere of 5% CO2 in air. As a positive control, responder cells were also
cultured with lmg/ml PHA (Murex Diagnostics, Temple Hill, Dartford, UK) for 3
days. Proliferation was assessed by adding 1 pCi/well 3H-thymidine (West of
Scotland Radionuclide Dispensary) during the final 18 hours of incubation and
DNA-bound 3H-thymidine was harvested using a Betaplate cell harvester (Wallac).
DSH has been defined by the relative response index (RRI) which is calculated by
the following formula:
RRI = (Recipient + Donor) - (Recipient + Recipient) x 100
(Recipient + Third Party) - (Recipient + Recipient)
where (Recipient + Recipient) represents the autologous background. Initially, I
used an RRI of < 20% as a definition ofDSH (Ghobrial 1994).
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MEASUREMENT OF CYTOKINE LEVELS BY ELISA
IL-2, IL-4, IL-10 and IFN-y
A sandwich ELISA was developed to measure IL-2, IL-4, IL-10 and IFN-y using
matched antibody pairs (R&D Systems, Abingdon, Oxon, UK). The optimal
concentrations of capture antibody, detection antibody, and standard were
determined using checkerboard protocols. Supernatants were harvested from MLR
cultures, centrifuged at 13, OOOg and stored at -20°C before use. 96-well flat-
bottomed plates (Nunc-Immuno) were coated with capture antibody in PBS (pH 7.2)
at a concentration of 4 pg/ml and incubated overnight at 4°C. The plates were then
blocked with PBS/ 1% bovine serum albumin (Sigma) for 2 hours at 37°C. 50 pi
culture supernatant in triplicate, and serial dilutions of recombinant human IL-2, IL-
4, IL-10 and IFN-y (R&D Systems) as standards in duplicate, were added to plates
and incubated overnight at 4°C.
The plates were then washed with PBS/ 0.05% Tween 20 and detecting antibody
(anti-IL-2 & IL-4: 12.5 ng/ml; anti-IL-10: 500 ng/ml; anti-IFN-y: 200 ng/ml) was
added for 3 hours at 37°C. Extravadin peroxidase (Sigma) was added for 2 hours at
37°C followed by TMB substrate (KPL, Maryland, USA) for approximately 20
minutes and the plates were read at 630 nm with a reference wavelength of 405nm
using an automated plate reader (Dynex Technologies). The concentration of
cytokine was calculated using standard curves derived from the recombinant
cytokines and the levels obtained using autologous stimulator cells were subtracted
to obtain donor-specific cytokine production.
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A time course study was then performed to determine the optimal day for harvesting
supernatants of the MLR. Cells from normal individuals were used as responders
and stimulators in the MLR, PHA was used as a positive control and supernatants
were harvested on Days 1 to 4. The secretion of IL-2, IL-4, IL-10 and IFN-y was
quantified on each day of the time course (Figure 2.4). The peak cytokine production
with stimulator cells was on Day 3 for all cytokines measured. The optimal day for
harvesting of supernatants stimulated with PHA was Day 1 for IL-4, Day 2 for IL-2
and IFN-y, and Day 3 for IL-10. As cell numbers were limited, supernatants from
PHA stimulated cells were harvested on Day 2 for all cytokines and from stimulator
cells on Day 3 for all cytokines.
TGF-p
Activated TGF-P 1 was quantified using a commercial 'Duo Set' kit (R&D Systems,
Abingdon, Oxon, UK). The block buffer consisted of 5% Tween 20, 5% Sucrose in
PBS with 0.05% NaN3. The diluent used for diluting standard, samples and
detection antibody, consisted of PBS (pH 7.3) containing 1.4% delipidized bovine
serum (R&D Systems, catalog #DY997) and 0.05% Tween 20.
Culture Conditions
Initially, I analysed TGF-p levels in supernantants of cultures performed in human
AB serum, as I did for other cytokines. However, as shown in Figure 2.5a, the
presence of serum produced very high background levels of TGF-p, obscuring any
differences between samples. I then attempted to culture the cells in the absence of
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serum, but this was also associated with background problems as shown in Figure
2.5b. For this reason, I eventually chose a method in which the cells were cultured in
AB serum for 24 hours, before transferring to serum-free conditions. As shown in
Figure 2.5c, this allowed more accurate differentiation of TGF-p production in the
background (autologous and culture medium) and test samples. A time course study
showed that the optimal day for harvesting of supernatants was Day 3 (Figures 2.5a-
c).
ELISA Method
A 96-well flat-bottomed plate (Nunc-Immuno) was coated with capture antibody (2
pg/ml) diluted in PBS and incubated overnight at 4°C. The plate was washed with
0.05% Tween 20 in PBS and blocked for 2 hours with block buffer. All samples were
activated prior to analysis by the addition of 25pl IN HC1 to 125 pi cell culture
supernatant for 10 minutes at room temperature. The sample was then neutralised by
adding 25pl 1.2 N NaOH/ 0.5 M Hepes and mixed well. Samples were diluted 2-
fold by adding 75pi of reagent diluent. A standard curve was constructed using
recombinant cytokine (2 ng/ml) in doubling dilutions and 50 pi activated samples
was added in triplicate and incubated overnight at 4°C. Detecting antibody (300
ng/ml) was added for a 3-hour incubation, before extravadin peroxidase in a
concentration of 1:1000 (Sigma) was added for 2 hours at 37°C followed by TMB






















































Figure 2.4: Time course of cytokine production during MLR and in response to PFIA.
Results shown are mean levels of IL-2 (a), IL-4 (b), IL-10 (c) and IFN-Y (d) in pg/ml
measured by ELISA after 1-4 days of culture of cells from a normal volunteer stimulated
with an unrelated volunteer (R/S) or 1 mg/ml PHA. BGD represents the background













































Figure 2.5: Time course of TGF-P production during MLR and in response to PHA.
Results shown are mean levels of TGF-P in ng/ml + 1 s.d. measured by ELISA after 1-3
days of culture of cells from a normal volunteer in 10% AB serum (a), serum free
conditions (b) or AB serum for the first 24 hours (c), stimulated with cells from an
unrelated volunteer (R/S) or 1 mg/ml PHA. MED represents the response obtained in
culture medium and BGD represents the background responses obtained from responder
cell stimulated with autologous stimulators.
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DETECTION OF mRNA EXPRESSION BY RT-PCR
ISOLATION of RNA
Cells were pelleted at 13 OOOg, washed in PBS at 4°C for 5 minutes, resuspended in
400 pi RNAZol™ B (Biogenesis Ltd, Poole, UK) and frozen at -70°C until ready
for use. In preparation for RNA extraction, the cells were thawed and 40 pi
chloroform was added. The sample was mixed vigorously for approximately 15
seconds, incubated on ice for at least 5 minutes and the resulting suspension
centrifuged at 13 OOOg for 15 minutes at 4°C. 200 pi of the upper clear phase was
carefully removed into a fresh RNAse-free Eppendorf to which 200 pi isopropanol
was added and stored on ice for 30 minutes or at 4°C overnight to allow the RNA to
precipitate. The lower blue phenol-chloroform phase was discarded and the sample
centrifuged at 13 OOOg for 15 minutes at 4°C. The supernatant was removed and the
RNA pellet was washed in 500 pi 75% ethanol for 5 minutes at 4°C. The pellet was
allowed to air dry before 10 pi sterile water was added and the pellet dissolved by
heating to 68°C in a dehybridiser for 2 minutes. The optical density was read and the
quantity ofRNA was calculated (40 pg/ml RNA — A260 of 1.000).
REVERSE TRANSCRIPTION
The volume of RNA needed for 2pg RNA and the volume of water needed to make
up a total volume of lOpl were calculated and the solution incubated in an Eppendorf
with 2pl random primers (GibcoBRL) for 10 minutes at 70°C and then cooled on
ice for at least 1minute. The RT mix was prepared using 2 pi lOx RT buffer
(GibcoBRL), 2 pi 25mM MgCl2 (GibcoBRL), 1 pi 10 mM dNTP (GibcoBRL), and 2
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[j,l 0.1M DTT (GibcoBRL) for each reaction. 7|ol RT Mix was added to each
RNA/primer mixture, vortexed gently and centrifuged at 6000 rpm for a few
seconds. The samples were then incubated for 5 minutes at 25°C before 1 [ol (200
units) Superscript II RT (GibcoBRL, Paisley, UK) was added to each reaction, which
were incubated for a further 10 minutes at 25°C, followed by 50 minutes at 42°C.
The reaction was stopped by incubating for 15 minutes at 70°C and cooled on ice.
PCR
The PCR for each cytokine was optimised by investigating different magnesium
concentrations and annealing temperatures for the primers listed in Table 2.2. All
primers worked well at a [MgCl2] of 1.5 mM and an annealing temperature of 60°C.
A PCR Mix was prepared, consisting of 5pl 10X PCR buffer (GibcoBRL), 3pi
25mM MgCl2 (GibcoBRL), lpl lOmM dNTP (GibcoBRL), 2.5pl of each primer
(40ng/ml, Sigma-Genosys, Cambridgeshire, UK) and 33pl distilled water for each
reaction. 47pl of PCR Mix was aliquoted into pre-labelled PCR tubes and 2pl of
cDNA was added to each tube, mixed and incubated for 2 minutes at 94°C in a DNA
thermocycler (Jenson, PLS, East Sussex, UK). The program was paused, lpl Taq
DNA polymerase (GibcoBRL) was added, and the mixture was allowed to incubate
for a further 3 minutes. 35 cycles of 94°C for 30 seconds, 60°C for 1 minute, and
72°C for 1 minute were followed by 72°C for 5 minutes and finally cooled at 4°C for
a maximum of 99 hours. The samples and a 50 base pair DNA ladder (GibcoBRL)
were analysed on 2% agarose gels (Gibco BRL) to which 20 pi ethidium bromide
(Sigma) was added. The gels were run on a electrophoresis power supply (BioRad,
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Hemel Hempstead, Herts, UK) using a UV transilluminator (Bio-Vision, Bio/Gene
LTd, Kimbolton, Cambs, UK).
Following optimisation of the assay, a time course study was carried out using cells
from volunteers to determine the optimal day for detecting IL-2, IL-4, IL-10, IFN-y,
and TGF-P gene expression. The house-keeping gene, P-actin, was detected in all
samples as shown in Figure 2.6a. In PHA stimulated cells, mRNA for IL-2 (Figure
2.6b), IL-10 (Figure 2.6d), IFN-y (Figure 2.6e), and TGF-P (Figure 2.6f) could all be
detected from Days 1-3. Gene expression in the allo-MLR could be detected on
Days 1 and 2 for IL-2 and IL-10, Day 2 only for IFN-y and throughout the time
course for TGF-p. IL-4 was very difficult to detect, but a weak band was seen in the
allo-MLR on Day 2 (Figure 2.6c).
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Figure 2.6: Time course of cytokine mRNA expression in MLR or in
response to PHA. p-actin (a), IL-2 (b), IL-4(c), IL-10 (d), IFN-y (e),
TGF-P (f) mRNA were assessed by PCR after culture for 1-4 days
(with autlogous stimulators (BGD - lanes 1, 5, 9, 13), allogenic
stimulator cells (lanes 2, 6, 10, 14), PHA (lanes 3, 7, 11, 15) and in
stimulators cells only (lanes 4, 8, 12, 16). Negative control wells
contained no mRNA (lane 17).
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STATISTICAL ANALYSIS
Clinical parameters (age, duration since transplant and serum creatinine) have been
expressed as medians and ranges for sub-groups of patients and were compared using
the Wilcoxon signed rank test, with p < 0.05 being considered significant. Cytokine
results were expressed as means and standard error of the means and were also
compared using the Wilcoxon signed rank test. Linear correlation was used to
determine the relationship between RRI and serum creatinine and cytokine
production. A receiver operating characteristic (ROC) curve was used to construct a
graphic representation of the relation between the sensitivity and specificity of the
laboratory test used to detect DSH over all possible diagnostic cut-off values
(Altman, 1994). The sensitivity and specificity of each observed data value was
calculated and the ROC curve was constructed by plotting sensitivity against 1-
specificity. The positive and negative predictive values of each potential cut-off of
RRI were also determined.
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CHAPTER 3: CADAVERIC COHORT
INTRODUCTION
At present, there remains no reliable method of identifying renal transplant patients
who are suitable for reduction of immunosuppressive therapy and the only strategy is
vigilance and early treatment of complications. The main aim of the Retrospective
Arm of the study was to determine whether donor-specific hyporesponsiveness
correlated with long term allograft outcome and the production of inhibitory
cytokines. This chapter describes the cadaveric cohort, which forms the main part of
this arm of the study. All the patients in this group had been transplanted for more
than five years and many had experienced adverse effects from long term
immunosuppression. Patients were divided into two groups based on allograft
outcome, with the hypothesis that patients with good allograft outcome were more
likely to show DSH and to produce inhibitory cytokines such as IL-4 and IL-10
compared with patients with poor graft outcome. Donor-specific hyporesponsiveness
(DSH) was identified by proliferation in mixed lymphocyte cultures, cytokine
secretion in MLR was measured by ELISA, and cytokine gene expression was
determine in selected patients by RT-PCR.
PATIENTS
Thirty-six adult recipients (21 male and 15 female) of cadaveric renal transplants
performed between February 1983 and March 1993 were studied. The inclusion
criteria were first graft recipients who had been transplanted for more than 5 years.
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The exclusion criteria were pregnancy and inability to give informed consent. The
aetiology of renal failure was: chronic glomerulonephritis (n=10), chronic
pyelonephritis (n=5), polycystic kidney disease (n=4), diabetic nephropathy (n=4),
hypertensive nephrosclerosis (n=2), congenital renal dysplasia (n=2), Alport's
syndrome (n=l), nephrocalcinosis (n=2), obstructive uropathy (n=l), post-partum
renal failure (n=l), and unknown (n=4). Most patients received one or more blood
transfusion during the course of renal replacement therapy prior to transplantation, as
treatment for anaemia and not as part of a planned pre-transplant blood transfusion
programme.
Classification of Patients
Patients were divided into two groups based on their history of acute and chronic
rejection and level of graft function, as outlined in Chapter 2. Group A comprised 10
male and 8 females and Group B comprised 11 male and 7 female patients. The
median age, time interval since transplant, degree of HLA-mismatch, serum
creatinine and rejection history of both groups are shown in Table 3.1.
Rejection History
Acute rejection was diagnosed on the basis of deterioration in graft function and
confirmed by percutaneous renal biopsy. Acute rejection episodes were treated with
high dose steroids and one patient had a steroid-resistant episode, which required
treatment with the monoclonal antibody OKT3. Chronic rejection was characterised
by a progressive decline in graft function with proteinuria and was confirmed by
percutaneous renal biopsy.
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Immunosuppression
The baseline immunosuppressive regimens used in both groups are shown in Table
3.2. Fourteen patients in Group A and eleven patients in Group B received dual
therapy (prednisolone combined with azathioprine or cyclosporin) and four patients
in Group A and seven patients in Group B received conventional triple therapy
(prednisolone, azathioprine, and cyclosporin). There were no changes in the regimen
throughout the course of transplant follow-up in patients in Group A. However, the
regimen for some patients in Group B was modified before or during the course of
the study period due to late (after the first three months) or multiple acute rejection
episodes and the development of chronic rejection (Table 3.2).
CLINICAL FEATURES OF CADAVERIC COHORT
There was no significant difference between patients in Group A and B with respect
to age, time since transplant or degree of HLA-mismatch. The degree of
sensitisation to HLA-antigens as measured by the panel reactive antibody (PRA)
level was also similar in the two patient groups (Table 3.1). As expected, patients in
Group A had a significantly lower median serum creatinine levels (102 pmol/L,
range 56-132) than patients in Group B (252 pmol/L, range 160-480, p= 0.0001).
Four patients in Group A experienced an early acute rejection episode (within the
first three months post-transplant), but these were steroid responsive and all patients
maintained excellent graft function throughout, with no graft losses. In Group B,
twelve patients experienced acute rejection: four patients had a single early acute
rejection episode and one of these was steroid resistant requiring OKT3 therapy; five
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patients had an acute rejection episode after the first three months post-transplant;
and three patients experienced multiple acute rejection episodes. Fifteen patients in
Group B had biopsy-proven chronic rejection, six of whom had no history of acute
rejection and there were five graft losses as a result of chronic rejection during the
course of this study (Table 3.1). The immunosuppressive regimens shown in Table
3.2 illustrate that more patients received cyclosporin as baseline therapy in Group B
compared with Group A (16 versus 11) and more patients were on a triple regimen in
Group B compared with Group A (7 versus 4), but these differences were not
statistically significant.
DONOR-SPECIFIC PROLIFERATIVE RESPONSES IN VITRO
To ensure that donor cells were sufficiently viable to act as stimulators in MLR, their
capacity to induce proliferation in a normal individual was tested in parallel with
cells from the recipient. Patients were excluded from the analysis if the donor or
recipient cell viability was poor, cell count too low or if the donor cells were unable
to induce proliferation in a normal control. As an additional check, some patient
samples were repeated to check for reproducibility of results. Pooled cells from five
normal volunteers were used as the third party control for all patients, as described in
Chapter 2. Mixed lymphocyte reactions were performed to assess the proliferative
response of each patient to their respective donor, third party cells and PHA. Parallel
plates were set up for cytokine analysis by ELISA and RT-PCR.
Donor-specific hyporesponsivness, as defined by an RRI in MLR of < 20%,
was detected in 18/36 (50%) patients overall. This consisted of 12/18 (67%) patients
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in Group A and 6/18 (33%) patients in Group B (Figure 3.1a), but this difference was
not statistically significant (X test, p=0.157). The mean RRI of patients in Group A
(14.7 ± 3.2) was significantly lower than that of Group B (36.7 ± 5.8, p=0.003). All
patients showed good proliferative responses after stimulation with third party cells
(Figure 3.1b) or PHA (Figure 3.1c) and there were no significant differences in these
responses between the two patient groups. DSH was detected in six patients in
Group B - four with chronic rejection, one with steroid-resistant acute rejection and
one with multiple episodes of acute rejection. Therefore, DSH was not confined to
patients with good allograft outcome.
The immunosuppressive regimes in patients who showed DSH and those who
did not were similar, as 15/18 (83%) patients with DSH and 13/18 (72%) patients
*i *• *t* *2without DSH had been maintained on cyclosporin-based immunosuppression (X
test, p>0.05). There was a significant correlation between the relative response
index and serum creatinine (r=0.531, p<0.001) when all patients of Groups A and B
were taken together (Figure 3.2). Twelve patients had both good graft function
(serum creatinine < 140 pmol/L) and DSH (RRI < 20%, dotted lines in Figure 3.2).
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GROUP A GROUP B
Figure 3.1: Proliferative responses of cadaveric recipients in Groups A (n=18)
and B (n=18). Results shown are the relative response indices (RRI) of each
group with DSH represented by the dotted line (a), (b) and (c) show the mean
3H-TdR incorporation of triplicate cultures of recipient responder cells after
stimulation with third party cells or PHA respectively. Group means are
represented by the lines, *p<0.05.
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RRI (%)
Figure 3.2: Correlation between the relative response index (RRI) and renal
function as determined by serum creatinine for Group A and B patients
combined (n=36). Dotted lines separate the patients with donor-specific




The cytokine profiles of patients in Group A were compared with patients in Group
B to determine whether there was a correlation with graft outcome. Lymphocytes
from patients in Group A produced significantly less IL-2 (p=0.017) and
significantly more IL-4 (p=0.015) than from patients in Group B when stimulated
with donor cells (Figure 3.3a). The two groups produced similar levels of IL-2 and
IL-4 following third party stimulation (Figure 3.3b). Although all patients showed
higher levels of IL-2 production in response to third party stimulator cells than in
response to autologous stimulators, recipients in Group A produced significantly less
IL-2 in response to their respective donors (Figures 3.4a and 3.4b) compared with the
levels produced following third party stimulation. Some patients in Group A also
produced higher levels of IL-4 in response to donor cells than in response to third
party cells (Figure 3.4c). Patients in Group B showed no differences in IL-2 or IL-4
production after donor or third party stimulation (Figures 3.4b and 3.4d). There were
no significant differences in IL-10 or IFN-y production between the two groups
following either donor (Figure 3.3a) or third party stimulation (Figure 3.3b).
When all patients were considered together, there was a significant correlation
between the RRI and both IL-2 (r=0.53, p<0.001, Figure 3.5a) and IFN-y production
(r=0.48, p<0.01, Figures 3.5b). There was also a significant negative correlation
bewteen the RRI and IL-4 production (r= -0.33, p<0.01, Figure 3.5c), but no
correlation between IL-10 production and RRI (Figure 3.5d). No data are available
on TGF-p production in this cohort as the TGF-P ELISA was not established at the
time when these patients were analysed and could not be performed retrospectively



























GROUP A GROUP B
Figure 3.3: Cytokine production by patients in Group A (n=18) and Group B
(n=18) in response to stimulation with donor (a) or third party (b) stimulator cells.
Results shown are mean cytokine production + SEM after subtraction of the





















Figure 3.4: Production of IL-2 and IL-4 by Group A (n=18) and B (n=18) recipients
after stimulation with autologous (recipient), donor (R/S) or third party (pool) cells.
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Figure 3.5: Correlation between the relative response index (RRI) and donor-
specific cytokine production in patients from Groups A and B combined
(n=36).
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EXPRESSION OF CYTOKINE mRNA
Fourteen patients in the Cadaveric Cohort, seven from each group, were analysed by
RT-PCR to give a sensitive indication of de novo cytokine production to assist
interpretation of the ELISA data. Only a limited number of patients could be
analysed in this way due to inadequate cell numbers and time constraints. In addition,
there was insufficient cDNA for some patients to analyse all the cytokines and in
these cases, I used PCR to confirm the absence of cytokine production when no
protein secretion could be detected by ELISA. The data for patients in Group A is
shown in Figure 3.6 and for Group B in Figure 3.7.
IL-2
IL-2 was assessed in thirteen patients. Gene expression was detected in three
patients, one from Group A (CD, Figure 3.6) and two from Group B (FH and SP,
Figure 3.7). Gene expression was not detected in eight patients in whom donor-
specific cytokine protein was secreted, three from Group A (GS, AS, and IPt, Figure
3.6) and five from Group B (GT, MB, SH, BN and AK, Figure 3.7). All the patients
who produced no measurable cytokine protein also showed no gene expression. IL-2
expression could not be assessed in two patients, both from Group A (JJ and IP,
Figure 3.6), as P-actin mRNA could not be detected when these cells were stimulated
with donor stimulators.
IFN-y
IFN-y gene expression was determined for thirteen patients, six from Group A and
seven from Group B. IFN-y was detected in six patients, one from Group A (GS,
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Figure 3.6) and five from Group B (GT, FH, MB, AK, and SP Figure 3.7). IFN-y
message was detected in one patient (AS, Figure 3.6) in whom no protein was
secreted, although in one other patient, no message was detected when cytokine
protein was produced (IPt, Figure 3.6). IFN-y message was not detected in three
patients in whom no protein was measure by ELISA, one from Group A (JR, Figure
3.6) and two from Group B (SH and BN, Figure 3.7). IFN-y expression could not be
assessed in two patients, both from Group A (JJ and IP, Figure 3.6), as p-actin
mRNA could not detected when these cells were stimulated with donor stimulators.
IL-4
IL-4 mRNA proved to be very difficult to detect, despite multiple attempts to
optimise PCR conditions with different primers and no reliable data were obtained.
IL-10
IL-10 gene expression was analysed in only six patients, three from each group. Of
these, IL-10 was detected in three patients when cytokine protein was measured by
ELISA, one from Group A (GS, Figure 3.6) and two from Group B (FH and SP,
Figure 3.7). IL-10 message was detected in one patient in whom no cytokine protein
was measured by ELISA (GT, Figure 3.7). The assay was unsuccessful in one patient
(AS, Figure 3.6). No gene expression was detected in one patient who produced no
cytokine protein (JR, Figure 3.6).
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TGF-p
TGF-p mRNA expression was assessed in thirteen patients, six from Group A and
seven from Group B. Many patients in both groups appeared to show donor-specific
TGF-P mRNA expression (GS, AS and IPt, Figure 3.6; all patients in Group B,
Figure 3.7), but this was also found in cells stimulated with autologous cells (lane 1),
third party stimulators (lane 3), and PHA (lane 4). As noted earlier, TGF-P protein
secretion was not measured in this cohort of patients.
Although these results showed that cytokine gene expression frequently
corresponded with the presence of cytokine protein as measured by ELISA, this was
not always the case and several instances occurred in which the two techniques gave
discordant results. Because of this, and because of technical problems with several of
the PCR methods, I did not pursue PCR analyses in other groups.
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P-ACTIN (387bp) IL-2 (375bp)
(0 pg/ml)
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P-ACTIN (387bp) IL-10(270bp)
(0 pg/ml)
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P-ACTIN (387bp) IL-2 (375bp)
(799 pg/ml)











Lane 7: Neg Control
















Lane 7: Neg Control
Figure 3.6 (a-g): IL-2, IL-4, IL-10, IFN-y and TGF-P mRNA expression
measured by RT-PCR in cells from patients from Group A. Lane 1 - autologous
control (BGD), Lane 2 - donor-stimulated cells (R/S), Lane 3 - Third party
stimulated cells (R/Pool), Lane 4 - PHA stimulated cells(R/PHA), Lane 5 -
stimulator cells (STIM, insufficient for some patients), Lane 6 - Third party cells
(Pool), Lane 7 - negative control. The levels of donor-specific cytokine protein
measured by ELISA in each patient are shown where appropriate.
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P-ACTIN (387bp) IL-2 (375bp)
(496 pg/ml)
Lane 1 2 34567 1234 5 6 7





Lane 3: R/Third Party
Lane 4: R/PHA
Lane 5: STIM
Lane 6: Third Party
Lane 7: Neg Control
bp Lane 1 2 3 4 6 7 1 2 3 4 6 7 Figure 3.7d: SH
Lane 1: BGD
Lane 2: R/STIM
P-ACTIN (387bp) IL-2 (375bp) Lane 3: R/Pool
(137 pg/ml)
Lane 4: R/PHA





Lane 7: Neg Control
76
bP Lane 1234567 1234567
P-ACTIN (387bp) IL-2 (375bp)
(430 pg/ml)
bP Lane 1234567 1234567














bp Lane 123467 12 3467








Lane 7: Neg Control
77
1 2 3 4 6 7
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Lane 7: Neg Control
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IFN-y (388bp) TGF-p (188bp)
(1133 pg/ml)
Figure 3.7 (a-g): IL-2, IL-4, IL-10, IFN-y and TGF-P mRNA expression
measured by RT-PCR in cells from patients from Group B. Lane 1 - autologous
control (BGD), Lane 2 - donor-stimulated cells (R/S), Lane 3 - Third party
stimulated cells (R/Pool), Lane 4 - PHA stimulated cells (R/PHA), Lane 5 -
stimulator cells (STIM, insufficient for some patients), Lane 6 - Third party cells
(Pool), Lane 7 - negative control. The levels of donor-specific cytokine protein
measured by ELISA in each patient are shown where appropriate.
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CLINICAL FEATURES OF DSH
Clinical parameters were assessed to determine whether patients who showed DSH
had more favourable pre-transplant criteria (including better HLA-matching and
lower levels of PRA), more intensive immunosuppression, or better post-transplant
graft function than patients without DSH. When patients were divided according to
the presence of or absence of DSH (RRI < 20%), irrespective of graft function, no
significant difference was found with respect to age, time since transplant, or degree
of total HLA-mismatch (Table 3.3). However, patients who showed DSH appeared
to be better matched at HLA-DR than those without DSH although this did not reach
statistical significance (Table 3.4). Although patients with DSH appeared to have
better graft function than those without DSH (median serum creatinine 115 pmol/1
versus 226 p.mol/1), this was not statistically significant (p=0.199). The
immunosuppressive therapy load was comparable, with 13/18 patients with DSH and
12/18 without DSH on dual therapy (prednisolone and either azathioprine or
cyclosporin), and 5/18 with DSH and 6/18 without DSH on triple therapy
(prednisolone, azathioprine and cyclosporin).
IMMUNOLOGICAL FEATURES OF DSH
Next, I compared the cytokine profiles of patients who showed DSH with those who
did not, to assess whether MLR-defmed DSH was associated with a particular pattern
of cytokines and also to determine whether there was any correlation with graft
outcome. The DSH group produced significantly less IL-2 (p=0.001, Figure 3.8a)
than the non-DSH group when stimulated with donor cells. All patients in the DSH
group produced higher levels of IL-2 in response to third party stimulation than after
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stimulation with donor cells, but three patients in the non-DSH group produced
higher levels of IL-2 in response to donor stimulation than after third party
stimulation. Patients who showed DSH did not appear to have generalised immune
suppression, as proliferation (Figure 3.8b and 3.8c) and IL-2 production (Figure 3.9a
and 3.9b) in response to either third party or mitogen stimulation was similar in the
DSFI and non-DSH groups.
Patients who showed DSH produced significantly more IL-4 (p=0.007) in
response to donor stimulation than those who did not show DSH. In addition, there
was no significant difference in the levels of IL-4 produced following third party
(Figure 3.9c) and mitogen stimulation (Figure 3.9d) in patients who showed DSH
and those who did not. There were no significant differences in donor-specific IL-10
and IFN-y production between the two groups (Figure 3.8).
To try and identify a sub-group of patients who might be candidates for
reduction of immunosuppression, I analysed further those patients who showed both
good allograft function and MLR-defined DSH. Twelve patients met these criteria
and eight of these produced higher levels of IL-4 than IL-2 in response to donor
stimulation (patients 5-12, Figure 3.10a). The remaining six patients who showed
DSH had poor graft function and only two of these produced higher levels of IL-4
than IL-2 (patients 14 and 18, Figure 3.10a). In the non-DSH group, only two
patients produced higher levels of IL-4 than IL-2 (patients 11 and 14, Figure 3.10b).
Four patients in the DSH group and one patient in the non-DSH group produced no
detectable IL-2 or IL-4 in response to donor stimulation. Therefore, a profile of low
IL-2 production /high IL-4 production is seen more often in patients who show DSH,
but this occurs irrespective ofwhether graft function is good or not.
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Table 3.3: Clinical features of cadaveric recipients who showed DSH



























p value 0.711 0.163 0.116 0.199
AGE TX: age at transplant, TIME TX: time interval since transplant.
M/M: degree of HLA-mismatch, CREAT: serum creatinine.
*Results are shown in medians and ranges. (Wilcoxin signed rank test).










0 12 6 0.066
1 5 10 0.176
2 1 2 0.229
DSH: donor-specific hyporesponsiveness










































Figure 3.8: Immunological parameters of donor-specific hyporesponsiveness. Donor-
specific cytokine production (a) and proliferative response to third party stimulator cells
(b) and PHA (c) in patients who showed DSH (defined as RRI < 20%) in MLR (n=18)
compared with those who did not (n=18). Results shown are mean concentrations of
cytokines + SEM for the two groups after subtraction of the background responses in
the presence of autologous stimulators (a), and the mean 3H-TdR incorporation for
triplicate cultures of individual recipient responder cells to stimulation with third party
cells (b) and PHA (c) . Group means are shown by the lines.
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Figure 3.9: IL-2 and IL-4 production by recipients in response to stimulation
with third party cells (a and c) and PHA (b and d) in patients who showed
DSH (defined as RRI < 20%) (n=18) and those who did not (n=18). Results
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Figure 3.10: Donor-specific IL-2 and IL-4 production in patients who showed DSH
(n=18) (a) and those who did not show DSH (n=18) (b), as defined by a RRI < 20%




1 initially analysed my data by defining the presence of DSH as an RRI of < 20%
between donor and third party stimulation. This was in line with previous
publications (Colombe et al, 1989; Ghobrial, 1994; Kim, 1996; Salomao et al, 1998;
Ishido, 1999) and the practice in the local Tissue Typing laboratory. However,
multiple definitions have been applied to define DSH in previous studies and most of
these have been performed prospectively with short-term follow-up. As my work
involved a single time point analysis of long-term graft survivors in a retrospective
study, it was possible that a different threshold for defining DSH may be required.
To test whether an RRI of < 20% was an appropriate definition of DSH for my data
set, I constructed a receiver operating characteristic (ROC) curve, using the method
described by Altman et al, 1994, to determine the optimal cut-off that maximised
both sensitivity and specificity of the index (Figure 3.11). The specificity of the test
was unchanged at 67% between a cut-off of 20-28%, but the sensitivity rose from
67% at a cut-off of 20% to 89% at a cut-off of 28%. I also calculated the positive
and negative predictive values of the assay at each possible cut-off value of RRI
(Table 3.5). A cut-off value of 28% yielded higher positive and negative predictive
values for the assay compared with my previous definition using a cut-off of 20%.
When I used an RRI of < 28% as a redefinition of DSH, 16/18 (89%) patients
with good graft outcome (Group A) and 6/18 (33%) with poor graft outcome (Group
B) showed DSH (p=0.005, Figure 3.12a). The level of graft function in the two
groups was also now significantly different, with a median serum creatinine of 115
pmol/l in the DSH group compared with 226 pmol/1 in the non-DSH group (p=0.004,
Table 3.6). There was still no significant difference in the median age (39.4 versus
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34.6 years, p=0.3) or duration since transplant (10.8 versus 10 years, p=0.18) in the
DSH and NON-DSH groups respectively. Although there was no significant
difference in the total HLA-mismatch between the two groups, DSH was again
associated with better HLA-DR matching, as 13/18 patients who had no mismatches
at the HLA-DR locus showed DSH (p=0.017, Fischer's Exact Test). Equal numbers
of patients were maintained on cyclosporin based immunosuppression (73% versus
79%) in the DSH and NON-DSH groups respectively. There was no significant
difference in the incidence of acute rejection episodes between patients who showed
DSH compared with those who did not (50% versus 43%), however significantly
fewer patients who showed DSH experienced chronic rejection (18% versus 79%,
p=0.003) (Table 3.3).
The cytokine profile of patients who showed DSH by this revised definition
showed even lower IL-2 production (p=0.011) and higher IL-4 production (p=0.01)
compared with non-DSH patients than suggested by the previous analysis (Figure
3.12b). As before, patients with DSH produced equal amounts of IL-2 in response to
third party stimulation (Figure 3.13a) and higher levels of IL-2 in response to
mitogen (Figure 3.13b) than patients without DSH. Although patients with DSH also
produced higher levels of IL-4 in response to third-party (Figure 3.13c) and
mitogenic (Figure 3.13d) stimulation, these differences were not statistically
significant.
In the previous analysis, DSH defined as a RRI < 20%, was identified in
twelve patients with good graft function, and eight of these patients produced higher
amounts of donor-specific IL-4 and low levels of IL-2 (Figure 3.10a). However as
described above, this cytokine profile was also detected in four other patients: two
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showed DSH, but had poor graft function and two did not show DSH, but one had
good graft function. When DSH was defined as RRI < 28%, sixteen patients with
good graft function showed DSH (Figure 3.14a). Of these, nine patients produced
higher levels of IL-4 than IL-2. Hence, one additional patient with good allograft
function was identified as showing MLR-defined DSH by the revised definition.
This patient (Patient 11, Figure 3.14a), had an RRI of 23% and produced almost two¬
fold higher levels of IL-4 than IL-2. A low IL-2/high IL-4 profile was also detected
in three other patients, all of whom had poor graft function: two showed DSH
(Patients 18 and 22, Figure 14a) and one patient did not show DSH (Patient 11,
Figure 3.14b).
In order to assess the relative production of donor-specific IL-4 and IL-2 in
patients who showed DSH and those who did not, the ratio of IL-4/ IL-2 was
determined in each group. When all patients were considered, the ratio of IL-4/ IL-2
production in patients who showed DSH was 2.07 compared with a ratio of 0.04 in
patients who did not show DSH. The ratio of IL-4/ IL-2 in patients with DSH and
those without DSH did not change significantly when the level of graft function in
each group was considered (Table 3.7). Therefore, patients who showed DSH
produced approximately two-fold higher levels of IL-4 than IL-2 in response to
donor stimulation, even in the presence of poor graft function, and patients who did
not show DSH produced a low donor-specific IL-4/ IL-2 ratio, even in the presence
of good graft function. Further analysis of the sixteen patients who showed DSH and
good graft function showed that only nine patients produced higher levels of donor-
specific IL-4 than IL-2 and the ratio of IL-4/ IL-2 production was 3.7.
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Figure 3.11: Receiver operating characteristic (ROC) curve for determining the
optimal level of RRI for defining donor-specific hyporesponsivenes (DSH). Results
shown are the sensitivity plotted against 1-specificity of multiple cut-off points. DSH
defined by a cut-off of 28% is shown in red.
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Table 3.5: The sensitivity, specificity, and predictive values of the















5 39 94 88 61
10 44 94 89 63
15 56 83 77 65
18 67 72 71 68
20 67 67 67 67
25 78 67 70 75
28 89 67 73 86
30 89 61 70 85
32 89 56 67 83
35 89 39 59 78
37 89 33 55 86
42 89 17 50 75
46 89 17 48 100
RRI: Relative response index.
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Table 3.7: Ratio of donor-specific IL-4/ IL-2 production in cadaveric














2.07 1.98 2.39 0.04 0.13 0.04
DSH: donor-specific hyporesponsiveness.
NON-DSH: donor-specific hyporesponsiveness not detected.
ALL: all patients in each cohort.
GOOD F'N: good graft function.























Figure 3.12: Immunological characteristics of patients with DSH defined as an
RR1 of < 28%. Results shown are individual and mean RR1 for Group A and
Group B with DSH defined by the dotted line (a) and the mean donor-specific
cytokine production + SEM after subtraction of the background responses in the
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Figure 3.13: IL-2 and IL-4 production by recipients in response to stimulation with
third party cells (a and c) and PHA (b and d) in patients who showed DSH (defined as
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Figure 3.14: Donor-specific IL-2 and IL-4 production in patients who showed DSH
(n=22) (a) and those who did not show DSH (n=14) (b), as defined by a RRI <28%.




This was a retrospective study of thirty-six cadaveric allograft recipients with long-
term graft survival and varied graft outcome. Patients in Group A had an
uncomplicated course with good allograft outcome and patients in Group B had a
poor allograft outcome with five patients returned to dialysis following graft failure.
In the latter group, late acute rejection and multiple or steroid-resistant episodes had
an impact on long-term graft function and may have also contributed to the
development of chronic allograft nephropathy.
This cohort of patients provided the main foundation of the retrospective
study and showed that donor-specific hyporesponsiveness and good graft outcome
correlated with the production of low levels of donor-specific IL-2 and high levels of
IL-4. A sub-group of patients with stable graft function was identified that showed
DSH with this favourable cytokine profile. To maximise the sensitivity and
specificity of the test, DSH was redefined as a RRI < 28% and this value was used
for the analysis of the living-related (Chapter 4) and malignancy (Chapter 5) cohorts
of the retrospective study and for the prospective cohort (Chapter 6).
95
CHAPTER 4: LIVING-RELATED COHORT
INTRODUCTION
Reduction of immunosuppression based on in-vitro assays has only been attempted
in living-related recipients, who have longer allograft survival due to better HLA
matching and shorter cold ischaemia after organ retrieval and hence are exposed to
immunosuppression for longer (Fletchner et al, 1989; Kerman et al, 1997). Despite
the fact that MLR-defined DSH is a common finding in such recipients, it has proved
difficult to use it as a reliable predictor of adverse events and acute rejection may still
occur following reduction of immunosuppression (Fletchner et al, 1989). Having
shown in Chapter 3 that a value of an RRI < 28% may be a better definition of DSH
and that donor-specific cytokine production may improve the discrimination between
good and poor graft outcome in cadaveric recipients, I went on to apply these
parameters in living related allograft recipients. This chapter describes experiments
in which 1 examined the correlation between graft outcome, MLR-defined DSH and
cytokine production in these patients.
PATIENTS
Fourteen patients (4 male and 10 female) were included. The numbers in this group
are relatively small due to difficulty in obtaining blood samples from the living
donors, many of whom were lost to follow-up, had moved out of the area, or had
died. All patients were first graft recipients with a functioning graft for more than
four years. The aetiology of renal failure was: chronic pyelonephritis (n=6), chronic
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glomerulonephritis (n=4), adult polycystic kidney disease (n=l), Goodpasture's
disease (n=l), congenital renal hypoplasia (n=l), and unknown (n=l). With respect
to HLA-typing, there were eight HLA haplo-identical (HLA-HI), five HLA-identical
(HLA-ID) and one non-identical (HLA-NI) recipients. One of the HLA-ID
recipients received a graft from an identical twin.
Classification of Patients
As with the Cadaveric Cohort, this group of patients had a mixed allograft outcome
and to allow direct comparison, I divided them into two groups using the same
criteria. Patients in Group A (n=8) had a good allograft outcome, with no acute
rejection beyond the first three months post-transplant and a serum creatinine <140
pmol/1 at the time of entry to the study. Patients in Group B (n=6) had a poor
allograft outcome, with either late or multiple acute rejection, or chronic rejection.
All rejection episodes were biopsy proven. To assess the role of HLA-matching in
graft outcome, the degree of HLA-match of Groups A and B was compared (Table
4.1). The clinical features of Groups A and B are shown in Table 4.2. Good graft
outcome was seen in 4/5 HLA-ID, in 3/8 HLA-HI and in the HLA-NI recipient.
Rejection History
Eight patients experienced acute rejection: five occurred early (within the first three
months post-transplant), one occurred late (after the first three months post-
transplant) and two patients had multiple acute rejection episodes. There were no
rejection episodes among the HLA-identical recipients. Three patients, two of whom
had experienced acute rejection, developed biopsy-proven chronic rejection. One
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recipient of an HLA-identical graft developed chronic rejection. Two of the patients
with chronic rejection subsequently lost their grafts, one of whom received a further
living-related graft from another sibling.
Immunosuppression
Ten patients received conventional triple therapy consisting of prednisolone,
azathioprine, and cyclosporin as baseline immunosuppression. The other four
patients received dual therapy: prednisolone and azathioprine in two patients, and
prednisolone and cyclosporin in two patients. Immunosuppression was modified in
six patients during the post-transplant course. The identical twin recipient, who
received dual therapy as a precaution, discontinued all immunosuppression three
months post-transplant. Four patients were converted to tacrolimus and one patient to
mycophenolate after rejection episodes.
Table 4.1: The degree of HLA-match for living-related recipients in
Groups A and B.




ID: identical, HI: haplo-identical, NI: non-identical.
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CLINICAL FEATURES OF LIVING-RELATED COHORT
The median serum creatinine of patients in Group A was significantly lower than in
Group B (104 pmol/1 versus 232 pmol/1, p=0.028). There were no significant
differences in age (p=0.917) or duration since transplantation (p=0.917) between the
two groups. Six out of eight Group A patients and all the patients in Group B,
received cyclosporin as baseline immunosuppression. The two patients who did not
receive cyclosporin were transplanted before cyclosporin was introduced into clinical
practice.
A few comparisons can be drawn between the living-related (LRD) and
cadaveric (CAD) groups. In comparison with the CAD Cohort, the LRD recipients
were younger (23.5 years versus 38.4 years) and had been transplanted for a shorter
duration (5.7 years versus 9.8 years), and these factors may influence the incidence
of DSH. The median serum creatinine was similar in Groups A (104 pmol/1 versus
102 pmol/1) and Groups B (232 pmol/1 versus 252 pmol/1) of the LRD and CAD
cohorts. There was also no significant difference in the acute rejection rate of Groups
A (38% versus 22%) and Groups B (83% versus 66%) in the two cohorts.
DONOR-SPECIFIC PROLIFERATIVE RESPONSES IN-VITRO
The MLR studies were performed and analysed as described in Chapter 3, with an
RRI of < 28% used as the definition of DSH. Using this definition, DSH was
detected in 9/14 (64%) living-related recipients. This consisted of 6/8 (75%) patients
in Group A and 3/6 (50%) patients in Group B (p=0.22, X2 test, Figure 4.1a). The
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mean RRI in Group A was 20.4 ± 9.3% and in Group B was 36 ± 12% (p=0.33). All
patients showed good proliferative responses after stimulation with third party cells
(Figure 4.1b) and PHA (Figure 4.1c). In comparison with the cadaveric cohort, there
was no significant difference in the mean RRI for patients in Groups A (20.4%
versus 14.7%) and Groups B (36% versus 36.7%). The living-related recipients also
showed levels of proliferation in response to third party cells and PHA similar to
those found previously in recipients of cadaveric grafts.
PRODUCTION OF CYTOKINES
IL-2, IL-4, IL-10, IFN-y
Lymphocytes from living-related recipients in Group A produced significantly lower
levels of IL-2 (p=0.03) and than those from recipients in Group B after stimulation
with donor cells (Figure 4.2). Group A patients also produced lower levels of IL-4
and IL-10 than Group B, but this was not statistically significant and both groups
produced similar levels of IFN-y (Figure 4.2). Compared with Group B, patients in
Group A produced higher levels of IL-2 and IFN-y in response to stimulation with
third party cells (Figure 4.3a and 4.3b) and PHA (Figure 4.3c and 4.3d), but almost
equivalent amounts of IL-4 and IL-10.
Donor-specific cytokine production appeared to depend on the degree of
HLA-matching. HLA-ID recipients produced virtually no cytokines in response to
donor cells, except for one patient (Patient 2) who produced predominantly IL-2.
This patient developed chronic rejection and subsequently lost the graft (Figure
4.4a). The identical twin recipient (Patient 4) produced only a low level of IL-4
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following stimulation with donor cells and no other cytokines. The profile of donor-
specific production by the HLA-HI recipients was variable, with IL-2, IFN-y and IL-
10 being the main cytokines found (Figure 4.4b). In contrast to the cadaveric
recipients, there was no significant correlation between the RRI and donor-specific
IL-2, IL-4, IL-10 or IFN-y production in the living-related cohort (Figure 4.5).
LRD recipients in both Groups A and B produced lower levels of all
cytokines in response to donor stimulation compared with their CAD counterparts,
probably reflecting the high proportion of HLA identical recipients. The lower
production of donor-specific IL-2 in LRD recipients in Group A compared with
those in Group B confirmed the results I found in the CAD recipients. However, the
LRD recipients in Group A did not show the higher production of IL-4 seen in CAD
recipients, nor was the significant correlations between the RRI and donor-specific








































GROUP A GROUP B
Figure 4.1: Proliferative responses of living-related recipients in Groups A and
B. Results shown are the relative response indices (RRI) of each group, with
DSH represented by the dotted line, (a), (b) and (c) show the mean H-
incorporation of triplicate cultures of recipient responder cells after stimulation














GROUP A GROUP B
Figure 4.2: Cytokine production by patients in Group A (n=8) and Group B
(n=6) in response to stimulation with donor cells. Results shown are mean
donor-specific cytokine production + SEM after subtraction of the background
responses in the presence of autologous stimulators.
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Figure 4.3: Cytokine production by living-related recipients in Group A (n=8) and Group
B (n=6) in response to stimulation with third party stimulator cells (a and b) or PHA (c
and d). Results shown are mean cytokine production + SEM after subtraction of the



































Figure 4.4: Cytokine production of HLA-identical (ID) (n=5) and HLA-haploidentical
(HI) (n=8) living-related allograft recipients after stimulation with donor cells. Results
shown are mean donor-specific cytokine production + SEM of triplicate cultures after
subtraction of the background responses in the presence of autologous stimulators in
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Figure 4.5: Correlation between the relative response index (RRI) and donor-specific
cytokine production in living-related recipients.
107
TGF-P Production in Living-related Allograft Recipients
TGF-P was measured by ELISA in this cohort of patients as the non-quantitative
PCR method I used to analyse TGF-p production in the cadaveric cohort showed that
it was difficult to discriminate between cells stimulated with donor, autologous or
third party cells in either Groups A or B.
LRD recipients in Group A produced lower levels of TGF-P protein than
patients in Group B in response to stimulation with donor cells, but this was not
statistically significant (p=0.07, Figure 4.6a). In contrast, Group A patients appeared
to produce higher levels of TGF-P in response to third party stimulation (Figure
4.6b). The HLA-ID recipients produced lower levels of donor-specific TGF-p than
the HLA-HI recipients, but this was not statistically significant (p=0.13, Figure 4.6c).
Similar to the other cytokines analysed, there was also no correlation between the
RRI and TGF-P production (Figure 4.7).
TGF-P production may be affected by the type of immunosuppression used
and it may also influence the development of chronic rejection. I found that patients
treated with tacrolimus (n=4) produced higher levels of donor-specific TGF-P than
cyclosporin- treated patients (n=6), although this was not statistically significant
(p=0.22, Figure 4.8a). In contrast, patients maintained on neither drug (n=4)
produced almost undetectable levels of TGF-P, although when compared to the two
other treatment groups, the differences did not reach statistical significance (p=0.08,
Figure 4.8a). Additionally, I found that patients with biopsy-proven chronic
rejection appeared to produce lower levels of TGF-P than patients without chronic














Figure 4.6: TGF-(3 production by living-related allograft recipients. TGF-P
production in patients of Groups A (n=8) and B (n=6) in response to stimulation
with donor cells (a) or third party cells (b). Donor-specific TGF-P production in
HLA-identical (ID) (n=5) compared with haploidentical (HI) (n=8) recipients (c).
Results shown are mean TGF-P production + SEM of triplicate cultures after
subtraction of the background responses in the presence of autologous
stimulators.
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Figure 4.7: Correlation between the relative response index (RRI) and donor-
specific TGF-P production in living-related allograft recipients (n=14).
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Figure 4.8: Donor-specific TGF-P production of patients maintained on
different immunosuppressive regimens and of patients with chronic rejection.
Results shown are mean TGF-P production + SEM after subtraction of the
background responses in the presence of autologous stimulators of patients
treated with cyclosporin (n=6), tacrolimus (n=4) or neither drug (n=4) (a), and
of patients with biopsy-proven chronic rejection (CR, n=3) compared with
those without (NO CR, n==l 1) (b).
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EXPRESSION OF CYTOKINE mRNA
I had examined mRNA expression in only a small number of living-related recipients
before I obtained the discordant results between PCR and ELISA analysis of
cytokine production in the cadaveric recipients. At this point, I abandoned the PCR
studies. Three patients were examined for cytokine mRNA assessment using RT-
PCR, two from Group B and one from Group A (Figures 4.9).
IL-2
Donor-specific IL-2 mRNA was detected in all three patients including the patient in
Group A in whom no measurable cytokine protein could be detected (GH, Figure 9).
IL-2 mRNA was detected in third party and PHA stimulated cells in all the patients.
IFN-y
Donor-specific IFN-y gene expression and cytokine secretion was also detected in
the two Group B patients (MH and CK, Figure 9). The Group A patient with good
graft outcome did not secrete IFN-y and no IFN-y mRNA was detected. In response
to stimulation with third party cells and PHA, IFN-y protein was secreted and mRNA
was detected by the Group B patients but the Group A patient showed no mRNA
expression although IFN-y protein was produced.
IL-4
The RT-PCR for IL-4 gene expression was unsuccessful.
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IL-10
Both Group B patients had shown donor-specific IL-10 protein production and both
had detectable donor-specific IL-10 expression of mRNA (MH and CK, Figure 9).
Both these patients had poor graft outcome. The Group A patient did not show
donor-specific gene expression or secretion of IL-10. All patients had IL-10 secretion
and mRNA after third party stimulation, although it was weak in two patients (GH
and MK). IL-10 mRNA was detected in all the PHA stimulated cells.
TGF-p
The Group B patient who produced high levels of TGF-p protein also had TGF-P
mRNA expression (MH), while the other Group B patient did not have detectable
protein or mRNA (CK, Figure 9). The Group A patient produced a low level of
TGF-P protein and had mRNA expression (GH, Figure 9). In response to third party
and PHA, TGF-P mRNA was detected and protein was secreted by the Group A
patient (GH) and one Group B patient (MH), but no mRNA expression was detected
in the other Group B patient (CK) when TGF-P protein was secreted.
There was a general correlation between donor-specific cytokine gene expression
and protein secretion in this group, although in one patient (GH), IL-2 mRNA was
detected when no cytokine protein was measured.
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Figure 4.9 (a-c): IL-2, IL-4, IL-10, IFN-y and TGF-P mRNA expression
measured by RT-PCR in cells from patients from living related recipients. Lane 1
- autologous control (BGD), Lane 2 - donor-stimulated cells (R/S), Lane 3 -
Third party stimulated cells (R/Pool), Lane 4 - PHA stimulated cells (R/PHA),
Lane 5 - stimulator cells (STIM), Lane 6 - Third party cells (Pool), Lane 7 -
negative control. The levels of donor-specific cytokine protein measured by
ELISA in each patient are shown where appropriate. Insufficient stimulator cells
were available for some patients.
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CLINICAL FEATURES OF DSH
The clinical features of patients with and without DSH are compared in Tables 4.3
and 4.4. There was no significant difference in the median age of these groups (23.4
years versus 23.5 years) and although patients with DSH had been transplanted for a
longer median duration than patients without DSH (7.7 years versus 5.3 years), this
was not statistically significant (Table 4.3). DSH was found in all of the HLA-ID and
3/8 HLA-HI recipients (Table 4.3). The only HLA-NI recipient did not show DSH,
but had a good graft outcome at 5 years post-transplant. The immunosuppressive
regimens of patients who showed DSH in the LRD group was similar to those in the
CAD group, with similar numbers of patients treated with cyclosporin, 75% versus
83% respectively. The incidence of DSH was also similar in Groups A (75% versus
89%) and B (50% versus 33%) in the LRD and CAD cohorts.
The level of renal function, as measured by serum creatinine, was similar in
patients who showed DSH and those who did not (127 versus 116 jumol/L) (Table
4.3). Patients who showed DSH experienced significantly fewer acute rejection
episodes than those who did not show DSH (44% versus 100%, p=0.036) (Table
4.3). DSH was detected in two patients with biopsy-proven chronic rejection, one of
whom was an HLA-ID recipient, however overall there was no significant difference
in the incidence of chronic rejection compared with patients who did not develop
DSH (22% versus 20%). Six patients in the living-related cohort showed DSH and
had good graft function (serum creatinine < 140 pmo1/1).
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IMMUNOLOGICAL FEATURES OF DSH
Similar levels of donor-specific IL-2, IL-4, IFN-y (Figure 4.10a) and TGF-P (Figure
4.10b) production were found in LRD patients with and without DSFI. Although the
DSFI group appeared to produce less donor-specific IL-10 than patients who did not
show DSH, this was not statistically significant (p=0.38, Figure 4.10a). Patients who
showed DSH had similar proliferative responses following stimulation with third
party (Figure 4.10c) and PHA (Figure 4.10d).
These findings contrast with the cadaveric cohort where patients with DSH
produced significantly lower levels of IL-2 and higher levels of IL-4 compared with
those who did not show DSH. Unlike the cadaveric cohort, a sub-group analysis of
the ratio of donor-specific IL-4 and IL-2 production in relation to DSH and graft




























































Figure 4.10: Immunological parameters of donor-specific hyporesponsiveness. Donor-
specific cytokine production (a and b) and proliferative response to third party stimulator
cells (c) or PHA (d) in patients who showed DSH (n=9) compared with those who did
not (n=5). Results shown are mean concentrations of cytokines + SEM for the two
groups after subtraction of the background responses in the presence of autologous
stimulators (a and b), and the mean H-TdR incorporation for triplicate cultures of
individual recipient responder cells to stimulation with third party cells (c) and PHA (d).
Group medians are shown by the bars.
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SUMMARY
Living-related allograft recipients with a good graft outcome had significantly lower
serum creatinine and produced significantly lower levels of donor-specific IL-2 than
patients with a poor graft outcome. All HLA-identical recipients showed DSH and
the level of donor-specific cytokine production appeared to be related to HLA-
matching, as the HLA-identical recipients produced low levels of all cytokines.
There was no significant difference in TGF-p production in patients maintained on
cyclosporin or tacrolimus based immunosuppression and there was no correlation
between donor-specific TGF-P production and chronic rejection.
In comparison to the cadaveric cohort, living-related recipients had similar
graft function and acute rejection rate in the corresponding graft outcome groups.
The incidence of DSH was also similar in the living-related (64%) and cadaveric
(61%) cohorts and DSH was detected in patients with chronic rejection in both
cohorts. Low donor-specific IL-2 production in patients with good graft outcome
was a consistent finding in both cohorts. However, a few differences were seen
between the living-related and cadaveric cohorts. Unlike the cadaveric cohort, there
was no association between graft outcome and IL-4 production in the living-related
cohort. A significant correlation was seen between RRI and IL-2, IL-4 and IFN-y
production in the cadaveric cohort, but there was also no correlation between RRI
and production of all cytokines in the living-related cohort. Although DSH was
associated with low donor-specific IL-2 production and high IL-4 production in
cadaveric recipients, there was no association between DSH and cytokine production
in the living-related cohort.
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CHAPTER 5: MALIGNANCY COHORT
INTRODUCTION
A confounding factor in most immunological studies of transplant recipients is the
effect of immunosuppression on the parameters which are to be measured. To try
and estimate the possible effects of this in my study, I included a cohort of patients
who had been maintained on low dose immunosuppression because they had
developed a de novo solid organ malignancy post transplantation. By definition,
these patients represent a group which have maintained good graft survival and a
lower incidence of acute rejection. I hoped this group would allow me to assess
better the significance of donor-specific hyporesponsiveness in transplant recipients
given conventional immunosuppressive regimens. Additionally, donor-specific
cytokine secretion has not been reported previously in patients of this kind.
Solid organ malignancy is often a fatal complication of transplantation with a
short life expectancy after diagnosis. Indeed, the incidence of cancer among
transplant recipients is estimated to be 3- to 4-fold greater than that of age-matched
controls in the general population (Penn, 1998). Additionally, the risk ofmalignancy
increases with the age of the recipient, type and duration of immunosuppression. As
older patients are being considered for transplantation, more potent
immunosuppressive agents are being used and graft survival has improved in the last
two decades, it seems likely that the incidence ofmalignancy will increase in years to
come. Therefore, it may become more important to identify patients at low risk of
adverse immunological events in whom immunosuppression could be safely reduced.
121
PATIENTS
Ten first cadaveric graft recipients who developed a de-novo non-skin malignancy
were entered in the study. Only a small number of patients was available for this
study, as survival following diagnosis of malignancy was generally short. The
tumours were 3 colo-rectal tumours, 1 gastric carcinoma with metastatic disease, 2
native renal tumours, 1 prostatic cancer, 1 non-small cell lung cancer and 1 patient
with a tonsillar lymphoma. The age, duration since transplant, degree ofHLA-match,
serum creatinine, primary malignancy, and time to diagnosis of malignancy are
shown for individual patients in Table 5.1. The median time to the diagnosis of
malignancy following transplantation was 10.2 years (range 2.6-13.6 years) and only
four patients were aged over 60 years at the time of diagnosis of malignancy. In this
cohort, 9/10 patients have had a functioning graft for more than 10 years at the time
ofmy study.
Immunosuppressive Regimens
Their immunosuppressive regimes at the time of recruitment were: prednisolone only
(n=4), prednisolone and azathioprine (n=3), and prednisolone and cyclosporin (n=3).
No patients were treated with OKT3 or polyclonal antibody therapy as part of the
initial immunosuppressive regimen or for treatment of acute rejection.
Rejection History
There were two early and no late acute rejection episodes. None of the patients had
chronic rejection. By comparison, none of the cadaveric (Chapter 3) or living-related
(Chapter 4) recipients without malignancy were maintained on monotherapy; 69% of
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the former and 29% of the latter received dual therapy; all other patients in these
cohorts received triple therapy.
CLINICAL FEATURES
The median age of patients in the malignancy group was 40.8 years (range 26.3-61.9
years, Table 5.2) and median duration since transplant was 12.7 years (range 4.8-15.9
years, Table 5.2). The median degree of HLA-mismatch was 3 (range 1-5) and
median serum creatinine was 105 pmol/L (range 82-183 pmol/L). One patient had
impaired renal function as a consequence of heart failure and presumed renal
hypoperfusion. Four patients died with functioning grafts during the study.
When compared with patients in the cadaveric cohort without malignancy,
there was no significant difference in age (40.8 years versus 39.1 years), the degree
of HLA-mismatch (3 in both groups), or the time since transplantation (12.7 years
versus 10.8 years, Table 5.2). In some clinical respects, the patients with malignancy
were analogous to patients in Group A of the cadaveric cohort, as their median serum
creatinine was 105 pmol/L, compared with 102 pmol/L in Group A and 252 pmol/L
in Group B patients without malignancy. In addition, the acute rejection rate in
patients with malignancy was 20%, compared with 22% in Group A and 66% in
Group B non-malignancy patients.
123

























































































AGETX:geattransplant,IMdurationsincetr l t,M/M:e rofHLA-ABdDR-mism tchC EAT:creati i e I/SUPPRESSION:immunosuppresion(PRED-predni lone,AZAazath opriCYCcyclosporin),TIMEDX:timefdiagn is ofmalignancy. 124






























AGETX:agettimoftr nsplant,TIME:durationsincetransplant,M/M:de r fHLA-AB,ndDR-misma ch, CREAT:creatinine,TIMEDX:duratiofollow gtranspla tthetimefdi gn sisal gnancy,AR:acutrej ction, CR:chronicrejection. CAD-GROUPA:goodraftoutcome,-GROUPB:po rgr ftout e.
*Resultsshownaretmediansndra ges.N/A:notappl cable.
125
DONOR-SPECIFIC PROLIFERATIVE RESPONSES IN VITRO
The mean RRI in the malignancy cohort was 21.3 ± 7.2% compared with 14.7 ±
3.2% in Group A and 36.7 ± 5.8% in Group B of the non-malignancy cadaveric
cohort (Figure 5.1a). Donor-specific hyporesponsiveness, as defined by an RRI <
28%, was detected in 9/10 (90%) patients with malignancy, compared with 22/36
(61%) of cadaveric recipients without malignancy overall, but this difference was not
statistically significant. The incidence ofDSH in the malignancy cohort was identical
to that of non-malignancy patients with similar graft outcome in Group A (90%
versus 89%) and was much higher than that of the patients with poor graft outcome
in Group B (90% versus 33%). Proliferative responses to third party cells (Figure
5.1b) and PHA (Figure 5.1c) in the malignancy group were comparable to those in
the non-malignancy cadaveric cohort, suggesting that there was no generalised
immunosuppression.
PRODUCTION OF CYTOKINES
Lymphocytes from patients with malignancy produced low levels of IL-2, IL-4 and
IFN-y, but produced high levels of IL-10 when stimulated with donor cells (Figure
5.2a). The mean level of IL-10 produced by these patients was approximately four¬
fold higher than any other cytokine produced and twice that found in the Group A
patients without malignancy who shared good graft outcome, although this was not
statistically significant. In Chapter 3,1 found that low IL-2 and high IL-4 production
was associated with good graft outcome in patients without malignancy. However,
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the patients with malignancy produced low levels of both IL-2 and IL-4, despite their
good graft outcome.
Compared with the cadaveric recipients in Group B who had a poor graft
outcome, the malignancy group produced similar levels of IL-10, lower levels of
IFN-y and significantly lower levels of IL-2 (p=0.009, Figure 5.2a). In response to
third party stimulation, patients with malignancy produced higher levels of IL-2 and
IFN-y and similar levels of IL-4 and IL-10 compared with both sub-groups of
patients without malignancy (Figure 5.2b). The level of IL-2 produced by the
malignancy group was lower than the non-malignancy sub-groups following
stimulation with PHA (Figure 5.2c), but similar levels of IL-4, IL-10 and IFN-y were
produced.
When all patients with malignancy were considered together, they produced a
lower mean level of IL-2 in response to donor stimulation than patients without
malignancy, but there were no significant differences in donor-specific cytokine
production between the two groups (Figure 5.3a). The patients with malignancy
who showed DSH produced higher levels of IL-2 than their counterparts without
malignancy, although they produced significantly lower levels when compared with
the Group B non-malignancy patients who did not have DSH (p=0.03, Figure 5.3b).
However, the malignancy group with DSH produced lower levels of IL-4 compared
with their non-malignancy counterpart and similar levels compared with patients
without DSH, although these differences were not significant (Figure 5.3b). PCR
studies were not performed in this patient cohort as discordant results were obtained











































MALIGNANCY GROUP A GROUP B
Figure 5.1: Proliferative responses of cadaveric recipients with malignancy
compared with patients in Groups A and B without malignancy. Results shown are
the relative response indices (RRI) of each group with DSH represented by the
dotted line (a), (b) and (c) show the mean 3H-TdR incorporation of triplicate
cultures of recipient cells after stimulation with third party cells or PHA























































MALIGNANCY GROUP A GROUP B
Figure 5.2: Cytokine production of cadaveric recipients with malignancy (n=10)
compared with patients without malignancy in Groups A (n=l8) and Group B
(n=18). Results shown are mean donor-specific cytokine production + SEM in
response to stimulation with donor cells (a), third party cells (b) and PHA (c)












































Figure 5.3: Donor-specific cytokine production of cadaveric recipients with
malignancy compared with patients without malignancy. Results shown are mean
donor-specific cytokine production + SEM after subtraction of background
responses in the presence autologous stimulators in patients with (n=10) compared
with those without malignancy overall (n=36) (a), and in patients with malignancy
who showed DSH (n=9) compared with those without malignancy who showed
DSH (n=22) or did not (n=14) (b).
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SUMMARY
The majority of the cadaveric recipients who developed a solid organ malignancy as
a complication post-transplantation shared some of the clinical and immunological
features I found in cadaveric recipients with good graft function that did not have
malignancy. These included good graft function, low acute rejection rate and DSH,
as measured by proliferation and low IL-2 production. Low IL-2 production was also
a consistent finding among living-related recipients with good graft outcome.
However, patients with malignancy appeared to produce more IL-10 and less IL-4
than non-malignancy cadaveric recipients with good allograft outcome. As the
patients in this study had no consistent evidence of generalised immunosuppression,
these results support the idea that a state of donor-specific hyporesponsiveness and
low donor-specific IL-2 production may partly explain their better graft outcome.
The other aim of my study was to determine whether donor-specific
hyporesponsiveness was associated with a particular pattern of cytokines, and my
data suggests that cadaveric recipients with or without malignancy who developed
DSH consistently showed low IL-2 production.
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CHAPTER 6: PROSPECTIVE STUDY
INTRODUCTION
There have been many reports of donor-specific hyporesponsiveness (DSH)
developing in renal allograft recipients following transplantation, but the production
of cytokines has never been correlated with the evolving DSH. Therefore, in this
arm of the study, I performed a prospective study to follow donor responsiveness
during the first year post-transplant and to determine whether patients who developed
DSH produced a particular pattern of cytokines. In Chapter 3, I showed that DSH
was associated with a favourable graft outcome and low donor-specific IL-2 and high
IL-4 production in long-term cadaveric graft survivors. If a similar cytokine profile
occurs in patients who develop DSH and maintain good graft function at the end of
the first year post-transplant, it could be a useful guide to tailoring
immunosuppression.
This chapter will describe the clinical and immunological features of
cadaveric and living-donor renal allografts recipients during their first year post-
transplant. The clinical course of all patients was followed for a further year to
assess graft outcome and to examine for the development of chronic rejection, which
is not commonly detected in the first year post-transplant. Patients were analysed for
donor responsiveness immediately before and at three, six and twelve months post-




All recipients of first cadaveric or live-donor renal allografts were eligible for this
arm of the study. The exclusion criteria were pregnancy and inability to give
informed consent. Most patients received one or more blood transfusions during the
course of renal replacement therapy prior to transplantation, as treatment for anaemia
and not as part of a planned pre-transplant blood transfusion programme. The
complement-dependent cytotoxicity crossmatch was negative before transplantation
in all patients.
CADAVERIC RECIPIENTS
Twenty-two adult recipients (17 male and 5 female) of cadaveric (CAD) renal
transplants performed between October 1998 and June 1999 were entered into the
study. Eight patients could not be analysed: two due to early graft failure, both
secondary to severe acute rejection; one withdrew from the study at 9 months follow-
up; three had poor recipient cell number and viability; and two had inadequate donor
cells. Therefore only 14 patients completed 12 months follow-up and were available
for analysis. The median degree of HLA-mismatch was 2 (range 0-6). The aetiology
of renal failure was: chronic glomerulonephritis (n=4), polycystic kidney disease
(n=3), chronic pyelonephritis (n=T), interstitial nephritis (n=l), Wegener's
granulomatosis (n=T), and unknown (n=4).
All patients received methylprednisolone lg intravenously immediately pre-
transplantation, thereafter conventional triple therapy consisting of prednisolone,
azathioprine and cyclosporin was given as maintainance therapy. Five patients
experienced acute rejection, of which four occurred early and one late (Table 6.1).
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Two patients developed chronic rejection and graft function declined. The
immunosuppressive regimen was modified in these seven patients as a result of acute
or chronic rejection, with four patients being converted from azathioprine to
mycophenolate, and three patients being converted from cyclosporin to tacrolimus.
LIVING-DONOR RECIPIENTS
Six adult recipients (all male) of living-donor (LD) renal allografts, performed
between October 1998 and May 1999 were entered into the study. Two patients
could not be analysed due to early graft failure: one due to steroid-resistant acute
rejection and the other as a result of renal vein thrombosis. The remaining four
patients all completed 12 months follow-up. With respect to HLA-matching: one
patient was HLA-identical (ID), two were HLA-haploidentical (HI), and one patient
who received a graft from his spouse was HLA-nonidentical (NI). The aetiology of
renal failure in these patients was: chronic glomerulonephritis (n=l), diabetic
nephropathy (n=l), congenital renal dysplasia (n=2).
All patients received methylprednisolone lg immediately pre-transplantation.
Thereafter, conventional triple therapy consisting of prednisolone, azathioprine and
cyclosporin was given as maintenance therapy. Three patients experienced acute
rejection - two occurred early, and one late (Table 6.1). The immunosuppressive
regimen was modified in these patients, with all being converted to tacrolimus from
cyclosporin following acute rejection. The HLA-ID recipient did not experience
acute rejection and none of the patients have developed chronic rejection.
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Table 6.1: Clinical features of patients followed prospectively for one
year.
GROUP AGE TX M/M PRA AR CR
(yrs) (%) EARLY LATE
CAD 47.9 2 2 4 1 2
(n=14) (24.6 - 64) (0-6) (0 - 32)




AGE TX: age at transplant, M/M: degree of HLA-A, B and DR-mismatch, PRA:
panel reactive antibody level, AR: acute rejection, CR: chronic rejection.
CAD: cadaveric, LD: living-donor.
*Results are shown as medians and ranges where appropriate.
Table 6.2: Renal function over the first 12 months post-transplant.
GROUP CREATININE (pmol/L)






















CAD: cadaveric, LD: living-donor.
*Results are shown as medians and ranges.
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CLINICAL FEATURES
The median age of the CAD recipients was 47.9 years (range 24.6-64 years) and 33.7
years (18.4-41.9 years) for the LD recipients. This difference did not reach statistical
significance (p=0.07, Table 6.1). There was also no significant difference in the
degree of sensitisation to HLA-antigens as measured by the panel reactive antibody
(PRA) level, or in serum creatinine levels pre-transplant and at 3, 6 and 12 months
post-transplant between CAD and LD recipients (Table 6.2). The baseline
immunosuppressive regimen was similar in both groups of patients, with all patients
receiving conventional triple therapy irrespective of HLA-matching and PRA status.
Nevertheless, the incidence of acute rejection was higher among the LD group than
the CAD group (75% versus 36%), although this difference was not statistically
significant. The level of graft function in CAD and LD recipients was monitored for
24 months to assess clinical stability. Two patients experienced late acute rejection,
one CAD recipient at 5 months post-transplant (Figure 6.1a) and one LD recipient at
18 months post-transplant (Figure 6.1b). The level of serum creatinine did not return
to its previous baseline in either patient. Two CAD recipients who showed
persistently sub-optimal graft function were found to have biopsy-proven chronic
rejection (Figure 6.1a).
Nine CAD recipients fitted the criteria for good graft outcome defined by
Group A in Chapter 3 as having good allograft function (creatinine <140 pmol/1)
with either no, or early steroid responsive acute rejection. The remaining five
patients had impaired graft function one year post-transplant and three of these met
the criteria for poor graft outcome, as defined by Group B in Chapter 3 (one
developed late acute rejection and two developed chronic rejection). Two LD
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recipients had good graft function despite early steroid-responsive acute rejection
and met the clinical criteria for Group A. One patient who experienced late acute
rejection had impaired graft function and met the criteria for Group B. The HLA-ID
patient had no rejection episodes, but had impaired graft function attributable to
obstructive uropathy and required nephrostomy and urological intervention.
DONOR-SPECIFIC PROLIFERATIVE RESPONSES IN VITRO
Recipient (responder) lymphocytes were obtained from blood taken immediately
before transplantation and thereafter at 3, 6 and 12 months post-transplant, always
before the morning dose of cyclosporin or tacrolimus at a routine clinic visit. Donor
(stimulator) cells were isolated by the local Tissue Typing Laboratory and stored
frozen until ready for use. As in Chapter 3, the capacity of donor cells to induce
proliferation by normal responder cells was tested to ensure their viability. Patients
were excluded from the analysis if the donor or recipient cell viability was poor, cell
count too low, or if the donor cells were unable to induce proliferation in a normal
control. As control stimulator cells, the pool of cells from five normal volunteers
was used as in Chapter 3. All the samples from all the time points from each patient
were analysed at the same time to avoid day to day variation in the assays.
The mean relative response index (RRI) immediately pre-transplant in the
CAD group was 63.4% compared with 145.7% (Table 6.3) in the LD group. Three
cadaveric and one living-donor recipient had a RRI < 28% prior to transplantation,
but did not all show DSH at one year post-transplant. Nevertheless, these patients
experienced no acute rejection, as they were well-matched to their donors. Although
the RRI fluctuated in most patients through-out the study period, at 12 months the
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mean RRI in each group was identical to that found pre-transplant (60.1% and
139.1% in the CAD and LD groups respectively). Notably, the HLA-NI recipient
experienced early acute rejection and remained strongly responsive to donor cells
through-out the time course with a RRI of 345.8% pre-transplant and 374.7% at 12
months post-transplant.
Table 6.3: RRI over the first 12 months post-transplant.
GROUP
RRI (%)
Pre-Tx 3 months 6 months 12 months
CAD
(n=14)
63.4 ± 11.6 73.1 ± 14.9 67.1 ± 19.2 60.1 ± 14
LD
(n=4)
145.7 ±71.7 178.5 ± 133.4 126.7 ±50.9 139.1 ±81.6
p value 0.34 0.49 0.36 0.41
RRI: relative response index, Pre-Tx: pre-transplant.
CAD: cadaveric, LD: living-donor (LD)
*Results are shown as means and SEM. (Wilcoxin signed rank test).
Among the cadaveric recipients, DSH defined as an RRI < 28%, was detected
in 3/14 (21%) patients at 3 months post-transplant, in 4/14 (29%) patients at 6
months post-transplant and in 5/14 (36%) recipients at 12 months post-transplant
(Figure 6.2a). At the end of the follow-up period, DSH was found in only 3 of the 9
cadaveric recipients who met the clinical criteria for good graft outcome and in one
patient who developed chronic rejection. The remaining cadaveric recipient who
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showed DSH had impaired graft function, but no history of acute or chronic
rejection. Among the 4 LD recipients, DSH was detected only in the patient who
received an HLA-ID graft and showed an RRI < 28% throughout the first year post-
transplant (Figure 6.2b). Although this patient had no acute rejection, graft function
was impaired and therefore did not meet the clinical criteria for good graft outcome.
All patients showed good proliferative responses after stimulation with third party
cells (Figures 6.3a,c) or PFLA (Figures 6.3b,d), with no significant differences in
these responses throughout the study period. Therefore, as I found in the
retrospective study described in Chapter 3, DSH was not confined to patients with
good allograft outcome and was not a result of general immune suppression.
Therefore, at 12 months post-transplant DSH was detected in 6/18 (33%) of
the patients. The level of donor responsiveness fell from the pre-transplant level in
all six patients who showed DSH at one year (Figure 6.4a). Of the twelve patients
who did not show DSH at one year post-transplant, the RRI rose in 3 patients (GM,
KM, and JR), remained virtually unchanged in 6 patients (AC, DM, GO, JH, JMc,
and JB) and fell in only 3 patients (GH, GD, JA) (Figure 6.4b). In addition, two of
these patients (KM and JR) had an RRI < 28% pre-transplant, but did not show DSH
at 12 months post-transplant. There was no significant difference in the pre-
transplant RRI between patients who developed DSH and those who did not, but
there was a significant difference in RRI between these patients at 3 (p=0.03), 6
(p=0.005) and 12 (p=0.004) months post-transplant (Figure 6.4c). DSH was not due
to general immune suppression, as the proliferative responses to third party cells
(Figure 6.5a and c) and PHA (Figures 6.5b and 6.5d) were similar in patients who























9 12 15 18 21 24
TIME (months)
GRAFT FUNCTION - LD JMc
JB
SMcK
Figure 6.1: Graft function over the first two years post-transplant of renal
allograft recipients followed prospectively. Results shown are the serum
creatinine of cadaveric (CAD, n=14) (a) and living-donor (LD, n=4) (b)
recipients over the first 24 months post-transplant, where the dotted line
represents good graft function as defined by serum creatinine <140 mmol/L.






Figure 6.2: Relative response indices (RRI) of individual cadaveric (a) and living-
donor (b) recipients over the first 12 months post-transplant. Results shown are
the RRI of cadaveric (n-14) (a) and living-donor (n=4) (b) recipients over the first
12 months post-transplant. DSH, defined as RRI < 28%, is represented by the
dotted line.
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Figure 6.3: Proliferative responses of cadaveric (CAD) and living-donor (LD)
recipients to stimulation with third party cells and PHA. Results shown are the mean
3H-TdR incorporation of triplicate cultures of recipient responder cells after
stimulation with third party cells (a and c) or PHA (b and d) in CAD (n=14) and LD




























Figure 6.4: Relative response indices (RRI) of patients followed prospectively
who developed DSH (n=6) compared with those who did not (n=12). Results
shown are (a) the RRI of individual patients over the first 12 months post
transplant of patients who developed DSH and (b) those who did not. (c) The
mean RRI + SEM of patients in both groups throughout the time course, where
DSH is represented by the dotted line.
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Figure 6.5: Proliferative response to third party stimulator cells and to PHA in patients who
showed donor-specific hyporesponsiveness (DSH) compared with those who did not. Results
shown are mean 3H-TdR incorporation of triplicate cultures of recipient responder cells after
stimulation with third party cells (a and c) or PHA (b and d) in patients who show DSH




The predominant donor-specific cytokine produced pre-transplant in cadaveric
recipients was IFN-y, although this was only observed in 8/14 patients and acute
rejection only occurred in two of these patients (Figure 6.6a). The level of IFN-
y secretion fell after 3 months, but there were no significant differences at any time
point. Although IFN-y also appeared to be the predominant cytokine at 12 months
post-transplant, this was seen in only 7/14 patients. Pre-transplant, IFN-y production
after donor stimulation exceeded the levels produced after third party stimulation, but
this difference was not significant and was only observed in 5/14 patients (Figure
6.6b). IFN-y production did not appear to correlate with acute rejection, as only two
of these patients experienced acute rejection. Similar levels of IFN-y were produced
at 3, 6 and 12 months post-transplant after donor and third party stimulation.
Donor-specific IL-2 production by cadaveric recipients remained high in the
first 3 months and fell after 6 months post-transplant, although this change was not
statistically significant (Figure 6.6a). IL-2 was the predominant cytokine in response
to donor stimulation pre-transplant in three patients (GO, AG and GH), with levels
exceeding those after third party stimulation, all of whom experienced early acute
rejection. As a group, IL-2 production in response to third party was higher than after
donor stimulation at all time-points within the first year post-transplant, but this was
only statistically significant at 12 months post-transplant (p=0.02, Figure 6.6b).
However, at 12 months post-transplant, the only patient (KM) who produced higher
levels of IL-2 with donor stimulation compared with third party stimulation had
stable graft function and no acute rejection episodes.
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Although the level of donor-specific IL-4 production among cadaveric
recipients appeared to rise at 12 months post-transplant, there were no significant
differences in IL-4 production throughout the first year post-transplant (Figure 6.6c).
IL-4 was the predominant cytokine in only one patient (AG) pre-transplant, who
experienced no acute rejection, maintained stable graft function and developed DSH.
In general, IL-4 production after donor stimulation exceeded the levels produced
after third party stimulation at 6 and 12 months post-transplant, but these differences
were not statistically significant and were seen in only 7/14 patients at each time
point (Figure 6.6d).
Donor-specific IL-10 production appeared to fall after 3 months and then
plateaued between 3 and 12 months post-transplant, but these differences did not
reach statistical significance (Figure 6.6c). IL-10 was the predominant cytokine in
only one patient (KM) pre-transplant, who experienced no acute rejection episodes.
IL-10 production in response to third party stimulation exceeded that produced after
donor stimulation in the first 3 months post-transplant, but this was seen in only 6/14
patients, and did not reach statistical significance (Figure 6.6d).
As I found in the cadaveric cohort of the Retrospective study, patients in the
prospective cohort with a good graft outcome at 12 months post-transplant (Group A,
n=9) also appeared to produce lower levels of donor-specific IL-2 and higher levels
of IL-4 than patients with poor graft outcome (Group B, n=3) (Figure 6.7). However,
these differences were not statistically significant as the sample size in Group B was
small.
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Figure 6.6: Cytokine production by cadaveric (CAD) recipients (n=14) during the first 12
months post-transplant. Results shown are mean cytokine production after stimulation with
donor (a and c) and third party (b and d) cells + SEM after subtraction of the background
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RETROSPECTIVE
Figure 6.7: Donor-specific cytokine production in cadaveric recipients at 12 months
post-transplant in the prospective cohort compared with the retrospective cohort based
on graft outcome. Results shown are mean donor-specific IL-2 and IL-4 production +
SEM after subtraction of the background responses in the presence of autologous
stimulators in patients with good graft outcome (Group A) compared with patients
with poor graft outcome (Group B).
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LIVING-DONOR GROUP
Low levels of all cytokines were produced pre-transplant in LD recipients in
response to donor stimulation. Levels of IL-2 remained low throughout the first 12
months post-transplant (Figure 6.8a), especially when compared with their cadaveric
counterparts. Surprisingly, donor-specific IL-2 production exceeded that produced
after third party stimulation at all time-points, but these differences were not
statistically significant (Figure 6.8b). As in the cadaveric recipients, donor-specific
IL-2 production pre-transplantation appeared to correlate with acute rejection
episodes. Indeed, 3/4 LD recipients (JA, JMcL and JB) showed higher IL-2
production after donor stimulation compared with third party stimulation before
transplantation and all of these patients experienced acute rejection. This trend was
maintained throughout the first 12 months post-transplant in two patients (JMcL and
JB).
Donor-specific IFN-y levels were also low, but increased somewhat during
the first year post-transplant (Figure 6.8a). Although IFN-y production before
transplantation was higher in response to third party than after donor stimulation, by
12 months post-transplant, donor-specific IFN-y production exceeded that found after
third party stimulation, but these differences were not statistically significant (Figure
6.6b). Similar to IL-2 production, two patients (JMcL and JB) produced higher
levels of IFN-y after donor compared with third party stimulation at 6 and 12 months
post-transplant.
No IL-4 was produced in response to donor stimulation before transplantation
in any of the patients, but the level increased throughout the first 12 months post-
transplant (Figure 6.8c). At 12 months post-transplant, IL-4 production after donor
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stimulation exceeded that produced after third party stimulation, but this was not
statistically significant (Figure 6.8d). Donor-specific IL-10 production appeared to
increase at 3 months post-transplant, but levels returned to baseline by 12 months
post-transplant (Figure 6.8c). IL-10 production in response to donor cells exceeded
third party stimulation at all time-points, but these differences were not statistically
significant (Figure 6.8d). Because of the small numbers of patients, I was unable to
perform a sub-group analysis based on graft outcome in the living-donor recipients in
the prospective study.
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Figure 6.8: Cytokine production by living-donor (LD) recipients (n=4) during the first 12
months post-transplant. Results shown are mean cytokine production after stimulation with
donor (a and c) and third party (b and d) cells + SEM after subtraction of the background
responses in the presence of autologous stimulators.
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GRAFT LOSS RECIPIENTS
Three patients had early graft loss as a consequence of acute rejection, but donor
cells were available for only two patients. The first patient NP, aged 34 years,
received a cadaveric graft which was poorly HLA-matched, had delayed graft
function and developed severe acute rejection with infarction necessitating graft
nephrectomy. The second patient CH, aged 35 years, received an HLA-
haploidentical graft from his brother, had immediate graft function but lost the graft
as a result of steroid-resistant acute rejection.
The proliferative responses pre-transplant by both patients to stimulation with
their respective donors exceeded third party stimulation, yielding an RRI of 146% for
NP and 111% for CH. In comparison to the cadaveric recipients who maintained
their grafts, only 3/14 of these patients showed an RRI exceeding 100%. NP and CH
showed good proliferative responses after stimulation with third party cells and PHA.
Cytokine analysis was performed on NP only, as recipient cell numbers for CH were
inadequate. Lymphocytes obtained pre-transplant from NP produced high levels of
IL-2 and IFN-y after stimulation with donor cells (Figure 6.9a), and these levels were
over two-fold higher than the mean cytokine production by cadaveric recipients who
maintained their grafts. Donor-specific secretion of IL-2 and IFN-y also exceeded
that produced following third party stimulation (Figure 6.9b), but was lower than that
produced after stimulation with PHA (Figure 6.9c). NP produced very low levels of







































Figure 6.9: Cytokine production in a cadaveric recipient, NP, with early graft loss secondary
to severe acute rejection. Results shown are mean cytokine concentrations of triplicate
cultures in response to stimulation with donor cells (a), third party cells (b) and PHA (c)
immediately pre-transplant.
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EXPRESSION OF CYTOKINE ink INA
As RT-PCR analysis had proved rather unreliable as a method for assessing cytokine
production in the previous arm of the study, I selected only two patients in the
prospective arm for PCR analysis. One of these, RW showed DSH (Figure 6.10a)
and the other, AC, did not (Figure 6.10b). IL-4 and TGF-P mRNA expression were
not assessed due to the problems I encountered with these in the retrospective cohort.
IL-4 proved difficult to detect despite many attempts to standardise the assay and
TGF-P mRNA expression was difficult to differentiate as it was found in cells
stimulated with autologous cells as well as the MLR.
IL-2
In the patient who showed DSH, donor-specific IL-2 mRNA expression was only
detected in the pre-transplant sample (RW, Figure 6.10a). This was consistent with
the results obtained by ELISA. IL-2 mRNA was detected in third party stimulated
samples, except at 3 months post-transplant, and in all PHA stimulated samples. In
the patient who did not show DSH, donor-specific IL-2 mRNA expression and high
levels of donor-specific IL-2 production were detected pre-transplant and at all time
points post-transplant (AC, Figure 6.10b). IL-2 mRNA was detected in all third
party stimulated samples, again apart from at 3 months post-transplant, and in all
PHA stimulated samples.
IFN-y
In the patient who showed DSH, donor-specific IFN-y mRNA expression and IFN-y
production were detected pre-transplant and at all time points post-transplant (RW,
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Figure 6.10a). IFN-y mRNA was also detected in all third party and PHA stimulated
samples. In the patient who did not show DSH, donor-specific IFN-y mRNA was
also detected at all time points and high levels of IFN-y production were found
throughout the first year post-transplant (AC, Figure 6.10b). IFN-y mRNA was only
detected in third party stimulated samples pre-transplant and at 12 months post-
transplant, but was present in all PHA stimulated samples.
IL-10
The patient who developed DSH showed IL-10 mRNA expression pre-transplant and
at 3 months post-transplant (RW, Figure 6.10a). IL-10 production was detectable by
ELISA pre-transplant and at 12 months post-transplant only. IL-10 mRNA was
detected in all third party and PHA stimulated samples. The patient who did not
develop DSH showed IL-10 mRNA expression at all time points, with high levels of
IL-10 measured by ELISA pre-transplant and also at 3 and 6 months post-transplant
(AC, Figure 6.10b), but no IL-10 was produced at 12 months post-transplant. IL-10
mRNA was detected in all third party stimulated samples, apart from 3 months post-
transplant, and in all PHA stimulated cells.
These results showed generally good correlation between donor-specific cytokine
gene expression and cytokine production as measured by ELISA in patients followed
prospectively. However, discordant results were obtained for some third party
stimulated cells for both patients. Therefore, like the retrospective study, PCR
studies were not pursued.
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Figure 6.10a: IL-2, IL-10, and IFN-y mRNA expression measured by RT-PCR
in cells from a cadaveric recipient followed prospectively for 12 months who
showed DSH. Lanes 1-4: pre-transplant, Lanes 5-8: 3 months post-transplant,
Lanes 9-12: 6 months post-transplant and Lanes 13-16: 12 months post-
transplant. BGD - autologous control, R/STIM - donor-stimulated cells, R/Pool -
third party stimulated cells, R/PHA - PHA stimulated cells. Lane 17 - stimulator
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Figure 6.10b: IL-2, IL-10, and IFN-y mRNA expression measured by RT-PCR
in cells from a cadaveric recipient followed prospectively for 12 months who did
not show DSH. Lanes 1-4: pre-transplant, Lanes 5-8: 3 months post-transplant,
Lanes 9-12: 6 months post-transplant and Lanes 13-16: 12 months post-
transplant. BGD - autologous control, R/STIM - donor-stimulated cells, R/Pool -
third party stimulated cells, R/PHA - PHA stimulated cells. Lane 17 - stimulator
cells (limited RNA available), Lane 18 - Third party cells (Pool), Lane 19 -
negative control.
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CLINICAL FEATURES OF DSH
As in the retrospective study, I compared the clinical and immunological features of
patients with and without DSH. When patients were divided according to the
presence of or absence of DSH (defined by an RRI < 28%) irrespective of graft
function, no significant differences were found with respect to age, degree of HLA-
mismatch, level of sensitisation as measured by PRA, or serum creatinine at one year
post-transplant (Table 6.4). Only 3/6 patients who showed DSH maintained good
graft function (serum creatinine <140 pmol/L) at 12 months post-transplant. As
noted above, I monitored graft function for a further year to assess graft outcome
beyond the period of in vitro analysis, but there was no significant difference in the
level of serum creatinine between patients with DSH and those without DSH
throughout the first two years post-transplant (Figure 6.11).
The immunosuppressive therapy load was comparable between patients with
DSH and those without DSH, all patients being maintained on standard triple therapy
(prednisolone, azathioprine and cyclosporin). However, the incidence of acute
rejection was significantly lower among patients who developed DSH than those
■j #
who did not (17% versus 58% respectively, p=0.01, X test). One patient from each
group developed biopsy-proven chronic rejection at the end of the 12-month follow
up period.
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Figure 6.11: Graft function during the first 2 years post-transplant of patients
followed prospectively who showed DSH (n=6) compared with those who did not
(n=12). Results shown are the mean serum creatinine + SEM over the first 24





IMMUNOLOGICAL FEATURES OF DSH
Next, I compared the cytokine profiles of patients who showed DSH with those who
did not. Patients who showed DSH produced low donor-specific levels of IL-2 pre-
transplant and throughout the 12-month follow up period (Figure 6.12a). All these
patients produced higher levels of IL-2 in response to third party stimulation than
donor stimulation at all time points (Figure 6.12b). Pre-transplant IFN-y production
in this group was higher in response to third party compared with donor stimulation
in all patients who developed DSH (Figures 6.12a and 6.12b). Thereafter, both
donor and third party IFN-y production fell, although these differences were not
statistically significant. Donor-specific IL-4 levels in patients with DSH appeared to
increase post-transplant and at 12 months post-transplant exceeded third party
production, but these differences did not reach statistical significance (Figures 6.12c
and 6.12d). At the end of the study period, donor-specific IL-10 production
remained essentially unchanged compared with pre-transplant levels and was lower
than third party production in patients who showed DSH (Figure 6.12c).
Patients who did not develop DSH within the first year post-transplant
produced high levels of IL-2 in response to donor stimulation before transplant,
although IL-2 production then decreased during the study period (Figure 6.13a).
Similar to the DSH group, third party-specific IL-2 production was higher than
donor-specific IL-2 production at all time points in patients who did not develop
DSH (Figure 6.13b). As in the patients who developed DSH, donor-specific IFN-y
production was highest immediately pre-transplant and decreased after 3 months
post-transplant (Figure 6.13a). However, unlike the DSH group, patients who did not
develop DSH produced higher levels of IFN-y pre-transplant after donor stimulation
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than after third party stimulation, but this was not statistically significant (Figure
6.13b). As in the patients with DSH, donor-specific IL-4 production appeared to
increase throughout the first year post-transplant and exceeded third party production
at 12 months post-transplant, but these differences were not statistically significant
(Figures 6.13c and 6.13d). IL-10 production in response to donor and third party
decreased throughout the study period, but again these differences were not
statistically significant (Figures 6.13c and 6.13d).
When donor-specific cytokine production by patients who showed DSH and
those who did not were compared directly, IL-2 production was lower in patients
who showed DSH compared with those who did not at all time points (Figure 6.14a).
However this was statistically significant only in pre-transplant samples. IFN-y
production was also lower in patients who showed DSH throughout the study period,
reaching statistical significance at 6 and 12 months post-transplant (Figure 6.14b).
IL-4 production pre-transplant and at 12 months post-transplant appeared to be
higher in patients who showed DSH than those who did not, but this was not
statistically significant (Figure 6.14c). Patients who developed DSH produced lower
levels of IL-10 pre-transplant than patients who did not develop DSH, although
similar levels of IL-10 were produced by the two groups at 12 months post-transplant
(Figure 6.14d).
In the retrospective arm of the study, I found that long-term cadaveric graft
survivors who showed DSH produced two-fold higher levels of donor-specific IL-4
than IL-2 and this was not seen in the patients who did not show DSH. In the
prospective study, patients who developed DSH produced 2.4 times higher levels of
IL-4 than IL-2 immediately pre-transplant, but only 1.3 times higher levels of IL-4
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than IL-2 at 12 months post-transplant as a group (Figure 6.15). As in the
retrospective study, good graft outcome was also associated with a trend towards low
IL-2 and high IL-4 production in the prospective cohort.
Only three of the patients in the prospective study developed DSH and
maintained good graft function at 12 months post-transplant. All were recipients of
cadaveric grafts. These patients showed a predominance of donor-specific IL-4
production over IL-2 production at 12 months post-transplant (Figure 6.16). At the
end of the study period, patient RW produced IL-4 but no IL-2, patient GC produced
4.2 times more IL-4 than IL-2 and patient AG produced 3.1 times more IL-4 than IL-
2. The three remaining patients with poor graft function who showed DSH produced
higher levels of IL-2 than IL-4 at 12 months post-transplant.
Similar to the retrospective cadaveric cohort, I assessed the ratio of donor-
specific IL-4/ IL-2 production in patients who showed DSH and those who did not
depending on graft outcome. Patients who showed DSH and had a good graft
outcome at 12 months post-transplant produced 4-fold higher levels of donor-specific
IL-4 than IL-2 (Table 6.5). However, unlike the retrospective cohort, patients with
DSH and poor graft outcome produced a similar IL-4/IL-2 ratio as patients who did
not show DSH (Table 6.5). Therefore, unlike the retrospective cadaveric cohort, low
IL-2 and high IL-4 production was seen only in DSH patients with good graft
function.
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Table 6.5: Ratio of donor-specific IL-4/ IL-2 production at 12















1.29 4.03 0.18 0.24 0.38 0.11
DSH: donor-specific hyporesponsiveness.
NON-DSH: donor-specific hyporesponsiveness not detected.
ALL: all patients in each cohort.
GOOD F'N: good graft function.
POORF'N: poor graft function.
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Figure 6.12: Cytokine production by patients who developed DSH (n=6) at 12 months post-
transplant. Results shown are the mean cytokine production + SEM after subtraction of
background responses in the presence of autologous stimulators after stimulation with donor
cells (a and c) and third party cells (b and d).
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Figure 6.13: Cytokine production by patients who do not develop DSH (n=12) within the
first year post-transplant. Results shown are mean cytokine production + SEM after
subtraction of the background responses in the presence of autologous stimulators after
stimulation with donor cells (a and c) and third party cells (b and d).
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Figure 6.14: Donor-specific cytokine production during the first 12 months post-transplant of
patients who developed DSH (n=6) compared with those who did not (n=12). Results
shown are mean production of IL-2 (a), IFN-y (b), IL-4 (c) and IL-10 (d) + SEM after




















Figure 6.15: Donor-specific cytokine production of patients who show DSH in the
prospective study (n=6) compared with those in the retrospective arm of the study
(n=22). Results shown are the mean IL-2 and IL-4 production + SEM after
subtraction of the background responses in the presence of autologous stimulators
pre-transplant (PROS-Om) and at 12 months post-transplant (PROS-12m) in the
prospective study, and in long-term graft survivors who show DSH in the


































Figure 6.16: Donor-specific cytokine production of patients with good graft function who
show DSH in the first 12 months post-transplant. Results shown are the mean IL-2 and
IL-4 production throughout the first year post-transplant of the three patients with good
graft function who showed DSH.
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SUMMARY
The prospective arm of this study included 14 cadaveric and 4 living-donor
recipients who completed one year of follow up. Although MLR-defined DSH was
found in 6/18 of the patients, only half of these maintained good graft outcome at the
end of the study period. As in the retrospective cadaveric cohort, good graft outcome
in patients with DSH appeared to be associated with low IL-2 and high IL-4
production. Indeed, a predominance of donor-specific IL-2 production over third
party production pre-transplantation appeared to correlate with acute rejection in
both cadaveric and living-donor recipients.
All patients with DSH who maintained good graft function at one year post-
transplant produced at least three-fold higher levels of donor-specific IL-4 than IL-2.
Patients who developed DSH also produced lower levels of IFN-y throughout the
study period compared with those who did not develop DSH, a finding which
contrasted with the lack of correlation between DSH and IFN-y production in the
long-term graft survivors in the retrospective study. There was no correlation
between graft outcome or DSH and IL-10 production in both arms of the study. At
one year post-transplant, it may be possible to identify cadaveric recipients who have
a lower risk of adverse events by the detection of DSH and low donor-specific IL-2
and high IL-4 production. In living-donor allograft recipients, good graft function
and low donor-specific IL-2 production may be useful prognostic indicators.
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CHAPTER 7: GENERAL DISCUSSION
INTRODUCTION
The incidence of end-stage renal failure is increasing and hence the demand for renal
transplantation is also increasing each year. As more powerful immunosuppressive
agents have been introduced and graft survival has improved, the incidence of
complications is likely to increase further due to longer cumulative exposure to
immunosuppression. Nevertheless, in some non-compliant patients and in some of
those with malignancy, excellent graft function can been maintained despite little or
no immunosuppression. This suggests that it may be possible to reduce the amount of
immunosuppression in some recipients without inducing rejection episodes and it
would be useful to be able to identify such patients.
Donor-specific hyporesponsiveness is a tolerance-like state that develops in
some allograft recipients and has been demonstrated in patients with and without
maintenance immunosuppressive therapy. The main objective of my study was to
determine whether immunological methods could assist in identifying suitable renal
transplant recipients for the reduction of immunosuppression. To achieve this
objective, I examined whether good graft outcome was associated with the presence
of DSH and a particular pattern of donor-specific cytokine production in long-term
graft survivors. I then went on to determine whether similar immunological features
could be found in patients who developed DSH within the first year post-transplant
to assess the optimal time for reducing immunosuppression.
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STUDY DESIGN AND METHODS
As long-term follow-up was not feasible during my research period, I chose to
perform a retrospective study of long-term graft recipients to determine if there was
any correlation between DSH or donor-specific cytokine production and graft
outcome. This arm of the study comprised sixty patients, forty-six cadaveric (CAD)
and fourteen living-related (LRD) recipients. These patients were selected on the
basis of graft function and rejection history to represent the two ends of the spectrum
of clinical outcome. The cadaveric group also included patients who had maintained
their grafts on low-dose immunosuppression after developing a solid organ
malignancy post-transplantation. The prospective arm studied the clinical outcome
and immunological features of eighteen patients, fourteen CAD and four LRD
recipients, at four time-points over the first year post-transplantation. As
approximately 80% of transplants performed in the West of Scotland each year are
derived from cadaveric donors, it is not surprising that cadaveric recipients
represented 77% of both ofmy study populations.
I then compared the findings from the two arms of the study to determine
whether patients with good graft outcome showed similar immunological features
which might be used as a guide in selecting patients for reduction of
immunosuppression. As described in Chapter 1, many in vitro techniques have been
used to assess the donor-specific immune responses of transplant recipients. In my
study, the MLR was used to detect DSH, as it has been shown to correlate with
favourable graft outcome (Bas et al, 1993; Reinsmoen et al, 1993; Ghobrial et al,
1994; Kerman et al, 1997; Creemers et al, 1997) and it is the only technique which
has been used in the selection of patients for reduction of immunosuppression
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(Fletchner et al, 1984, Kahan et al, 1989, Kerman et al, 1997). This method is also
easier and quicker than limited dilution assays, particularly when analysing large
numbers of patients. As there is no consensus on the method used to define DSH as
measured by MLR, I decided to use the relative response index, as it is a simple
method that provides a single value which takes both donor reactivity and responses
to third party control into account.
When I began my work, I used an RRI of < 20% to define DSH, a value used
both by other investigators (Colombe et al, 1989; Ghobrial, 1994; Kim, 1996;
Salomao et al, 1998; Ishido, 1999) and by the local Tissue Typing Laboratory in the
selection of bone marrow donors. However, by the end of the study of the cadaveric
cohort, I became aware that this may not have been the best value to show the
discriminatory power of the MLR as a diagnostic test for detecting DSH. Therefore,
I constructed a receiver operating characteristic curve, using the method described by
Altman et al (1994), to determine which RRI was the best cut-off for defining poor
graft outcome. When all values were considered, the highest sensitivity of the assay
in detecting patients with a good graft outcome was 89% when the cut-off value of
RRI was 28% or above. The highest specificity of the assay in detecting patients with
a poor graft outcome was 94% when the cut-off value ofRRI was 10% or below. As
the cut-off level of RRI increased, sensitivity of the assay increased and specificity
decreased, but the specificity was identical when a cut-off of 20% and 28% was
applied. However, the sensitivity of the assay increased from 67% when a RRI of
20% was used, to 89% at a cut-off of 28%.
The predictive value of the assay was also assessed at each cut-off point. The
positive predictive value of the assay in detecting the proportion of patients with a
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good outcome was 67% using a cut-off of 20% compared with 73% when using a
cut-off of 28%. The negative predictive value of the assay in detecting the proportion
ofpatients with a poor graft outcome was 67% using a cut-off of 20% compared with
86% when using a cut-off of 28%. These results suggest that the sensitivity,
specificity and predictive power of the MLR in detecting DSH were greater when a
cut-off of 28% was used. The cadaveric cohort was therefore re-analysed using an
RRI of 28% as the definition of DSH and this was subsequently applied to all
patients studied.
LIMITATIONS OF STUDY
The data presented in my study should take into account several limiting, albeit
frequently unavoidable factors in the study design and methodology.
STUDY DESIGN
The cadaveric cohort in the retrospective arm of the study was designed to compare
patients with clinical features of good compared with poor graft outcome. The
criteria used to define the outcome groups were subjective and an arbitrary level of
serum creatinine (< 140 pmol/L) was used to define good graft function. The study
size was limited further by the fact that sufficient donor material was not available
for all the patients who met these criteria in the transplant database. Patients with
poor graft function were difficult to recruit, and the number of patients was further
restricted by the fact that many had lost their grafts due to chronic rejection. The
patients with poor graft outcome were also relatively heterogeneous, as this group
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included patients with late, multiple or steroid resistant acute rejection episodes,
although chronic rejection was the main cause of graft dysfunction. Uraemia has
been shown to impair lymphocyte function (Frymoyer et al, 1985; Kurz et al, 1986)
and may have affected the proliferative responses in patients with poor graft
function. However, I found that patients with impaired graft function had
proliferative responses to third party and PHA similar to those in patients with good
graft function, although both these groups had generally lower responses than non-
immunosuppressed controls.
As only 10-20 living-related transplants are performed each year in the West
of Scotland, the number of patients in this group was relatively small compared with
the cadaveric pool in both arms of the study. The number of long-term living-donor
recipients was further limited by the availability of the donor, some of whom were
difficult to trace, or had died. Only six living-related transplants were performed
during the recruitment period of my prospective study, and as two of these grafts
failed, the study group was small and sub-group analysis could not be performed.
Immunological studies involving transplant patients are complicated by the
use of immunosuppression. As it is unethical to reduce or stop treatment for the
purpose of laboratory tests, I attempted to minimise the effects of
immunosuppressants by taking all blood samples before the morning dose of
cyclosporin or tacrolimus. The pre-transplant sample in the prospective cohort was
also obtained before the first dose of immunosuppression. Any changes in
immunosuppressive therapy were recorded but it is possible that these changes may
have influenced immune responses.
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METHODS
I performed a number of experiments to determine the best choice for a third party
control. Previous studies have used a variety of such controls, including peripheral
blood lymphocytes from random unrelated HLA-DR mismatched volunteers, or
unrelated volunteers with a degree of HLA-mismatch similar to that in the recipient-
donor pair, or a panel of individual or pooled volunteers. Alternatively, a panel or
pool of donor splenocytes has been used as stimulators. As my work was not carried
out in a tissue-typing laboratory, I could not use a source of third party controls that
required known HLA-disparities, or which required large numbers of donor cells.
Therefore, I used a pool of unrelated volunteers to represent a 100% reference
control to which all recipients were tested. This allowed for all patients to be tested
against the same easily obtainable third party controls, but the main disadvantage
was that an MLR against pooled stimulator cells does not reflect exactly the MLR
response against the donor, as more HLA-DR antigens are present to stimulate
recipient cells.
Although I was able to test the reproducibility of the MLR in some patients, I
could not verify my results for all patients as donor material was limited. However, I
assessed the viability of donor cells before setting up the MLR in all patients to
reduce the possibility of erroneous results. Additionally, I assessed the proliferative
response of a volunteer against donor cells as a test of their functional viability.
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RETROSPECTIVE STUDY
CADAVERIC AND LIVING-RELATED COHORTS
The cadaveric group without malignancy which consisted of thirty-six patients,
provided the main foundation of the retrospective study. Despite many similar
clinical features, such as age and duration since transplantation, patients who
developed DSH were better matched at the HLA-DR locus than patients who did not
develop DSH. This is consistent with the fact that alloreactive Class II MHC
restricted CD4+ T cells play the most important role in mixed lymphocyte cultures
(Reinsmoen, 2002). Although many previous studies which explored DSH following
cadaveric renal transplantation did not state the degree of HLA-match, and
Reinsmoen et al (1993) reported no correlation between DSH and the degree of
HLA-DR match, Ghobrial et al (1994) reported a higher frequency of HLA-DR
compatibility in association with DSH, although this was not statistically significant.
Overall, 61% of the cadaveric recipients in my study had DSH when
examined at a median time of 9.8 years post-transplant. The longest prospective
follow-up study reported previously was only of 4 years duration and found an
incidence ofDSH of 32% only (Kerman et al, 1997). As it has been shown that there
is a trend towards lower donor-specific MLR responses in patients transplanted for 8-
12 years compared with those transplanted for 2-5 years (Thomas et al, 1977), this
may explain the higher incidence of DSH in my cohort compared with that of
Kerman et al.
In comparison, 57% of the living-related recipients in my study had DSH at
median time of 5.7 years post-transplant. All of the HLA-ID patients and 38% of the
HLA-HI showed DSH. DSH was not found in the HLA-NI recipient, despite a good
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graft outcome. My findings are consistent with reports of DSH in 95-100% ofHLA-
ID recipients and 31-47% of HLA-HI recipients within the first two years post-
transplant (Fletchner et al, 1984; Kahan et al, 1989; Kerman et al 1997). However,
one other study has reported DSH in 75% of HLA-HI recipients (Kim et al, 1996).
This discrepancy may be explained by the selection criteria used by Kim et al, who
included only patients with good graft function who had no history of acute rejection
and had been transplanted for up to 8 years. I could find no reports on the incidence
ofDSH in HLA-NI recipients.
Although I found a higher incidence of DSH in both cadaveric and living-
related recipients with a good graft outcome compared with those with a poor graft
outcome, there was a significant correlation between DSH and graft outcome only in
the cadaveric cohort. Other groups have shown an association between DSH and
better long-term graft survival in both cadaveric (Reinsmoen et al, 1993; Ghobrial et
al, 1994; Kerman et al, 1997) and living-related (Reinsmoen et al, 1993; Kim et al,
1996; Kerman et al, 1997; Salomao et al, 1998) recipients. The lack of a significant
correlation between DSH and graft outcome in my living-related cohort may reflect
good HLA-matching even among the patients with poor graft outcome, as well as the
greater heterogeneity ofmy small group compared with other series.
Not surprisingly, I found that both cadaveric and living-related recipients
with a good graft outcome had significantly lower levels of serum creatinine than
patients with a poor outcome, even though serum creatinine was not one of the
criteria used to define poor graft outcome. In the cadaveric cohort, I found a
significantly lower serum creatinine in patients with DSH compared with those
without DSH and the RRI correlated significantly with serum creatinine levels.
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These features were not observed in the living-related group who consisted of a
smaller group with shorter duration of graft function. In contrast, previous reports
have shown no correlation between DSH and the level of graft function as measured
by serum creatinine in cadaveric recipients (Reinsmoen et al, 1993; Ghobrial et al,
1994), although one of these studies (Reinsmoen et al, 1993) did report lower mean
serum creatinine levels in living-related recipients. Again, the discrepancy between
my study and these earlier ones may be the differences in time after transplant, as
well as the small size ofmy living-related cohort.
The overall incidence of acute rejection in my cadaveric recipients who
showed DSH was similar to those who did not (50% versus 43%), but the incidence
of rejection was significantly lower in living-related recipients who showed DSH
compared with those who did not (44% versus 100%). As discussed in Chapter 1,
the timing of acute rejection episodes is an important factor and acute rejection after
the first three months post-transplant has been shown to have the greatest impact on
graft survival (Joseph et al, 2001; Sijpkens et al, 2003). Thus, when early steroid-
responsive rejection episodes were excluded from my analysis, DSH was associated
with fewer late and multiple acute rejection episodes in both cadaveric and living-
related recipients. This is consistent with the findings of other groups which showed
a reduced incidence of late acute rejection in patients with DSH (Reinsmoen et al,
1993; Ghobrial et al, 1994; Kerman et al, 1997; Creemers et al, 1997).
DSH was not confined to patients with good graft function, as it was also
found in two patients with late or recurrent acute rejection episodes, as well as in
four cadaveric and two living-related recipients with chronic rejection. This supports
other reports which have shown that chronic rejection may be found in some patients
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who show DSH (Reinsmoen et al, 1994; Bohmig et al, 2000) and suggests that
chronic rejection may not be entirely immune mediated. More recently, it has been
shown that the risk of chronic rejection in patients who show DSH is higher among
those patients who have experienced acute rejection compared with those who have
been free of acute rejection (Reinsmoen et al, 2002). However, patients who
experience acute rejection have a higher risk of chronic rejection if they remain
responsive to their donor compared with those who develop DSH. Together these
results suggest that DSH is not exclusive to patients with a good graft outcome and
that the risk of chronic rejection is lower in patients who develop DSH.
My studies of donor-specific cytokine production also gave discordant results
in the two groups of recipients. In the cadaveric cohort, DSH and good graft
outcome were associated with the production of low levels of donor-specific IL-2
and high levels of IL-4 and there was a significant correlation between the RRI and
donor-specific IL-2, IL-4 and IFN-y production. In the living-related cohort, DSH did
not correlate with donor-specific cytokine production, good graft outcome was
associated only with low levels of donor-specific IL-2, and there was no correlation
between RRI and cytokine production. In fact the living-related group, particularly
HLA-ID recipients, produced low levels of all cytokines in response to donor
stimulation, which again may reflect the high degree of HLA-compatibility in this
group. The level of immunosuppression in patients who developed DSH and those
who did not was similar in both cohorts and DSH itself was not due to generalised
immune suppression, as all patients showed good proliferative responses and
cytokine production in response to stimulation with third party cells and PHA.
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The correlation between the donor-specific proliferative response and IL-2
production in cadaveric recipients was not unexpected, given the role of IL-2 as a T
cell growth factor. However, IL-2 also appears to be essential for tolerance by
facilitating the deletion of alloreactive T cells through activation-induced cell death
(Zheng et al, 2000) and the development of regulatory T cells in the periphery
(Furtado et al, 2002; Li et al, 2003). For these reasons, there is now concern that
immunosuppressive agents that inhibit IL-2 production, such as cyclosporin and
tacrolimus, may block tolerance. This is supported by the findings that the
administration of high dose calcineurin inhibitors at the time of tolerance induction
prevents long-term graft survival (Larsen et al, 1996; Kirk et al, 1999) and the
development of CD4+ CD25+ regulatory cells (Wood et al, 2003). Although
rapamycin interferes with IL-2 signalling, it does not appear to have a similar effect
on AICD, although its effect on regulatory cells remains unclear (Wood et al, 2003).
My data are consistent with the idea that the level of donor-specific IL-2 may have
complex effects on the allospecific immune response, with high levels stimulating
clonal expansion and low levels facilitating tolerance.
The negative correlation between the relative response index and IL-4
production suggests that IL-4, and/or IL-4 dependent cells, may play a role in the
maintenance of donor-specific tolerance. These findings are consistent with other
evidence for IL-4 producing regulatory T cells in allograft tolerance induced by
donor-specific transfusion (Yang et al, 1998) and with the fact that tolerance-
inducing regimens often suppress IL-2 but not IL-4 gene transcription (Nickerson et
al, 1993; Chen et al, 1996; Mottram et al, 1995; Onodera et al, 1997). Furthermore,
infectious tolerance in which CD4+ T cells can adoptively transfer specific tolerance
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to a naive host by suppressing the ability of host cells to effect allograft rejection,
appears to be driven by IL-4-dependent immune deviation (Davies et al, 1996;
Bushell et al, 1999; Ke et al, 2000). IL-4 may facilitate allograft tolerance either by
promoting Th2 differentiation with a resultant decrease in inflammatory Thl activity,
or by acting as a growth factor for regulatory T cells (Li et al, 1999; 2003).
The significant correlation between the degree of donor responsiveness and
IFN-y production in cadaveric recipients suggests a possible correlation between a
poor allograft outcome and a Thl profile. IFN-y is generally regarded as a pro¬
inflammatory cytokine and increased intra-graft IFN-y expression is frequently
detected in rejecting allografts, while decreased expression is found in long-term
surviving grafts (Takeuchi et al, 1992; O'Connell et al, 1993; Sayegh et al, 1995).
Although some reports suggest that IFN-y may have a protective role after
transplantation, as the administration of anti-IFN-y antibody has been shown to lead
to rapid allograft rejection (Markees et al, 1998; Konieczny et al, 1998), a recent
study supports my findings by showing that HLA-DR allopeptide-specific T cell
clones generated from recipients with chronic rejection secrete IFN-y, while clones
from recipients with stable graft function produce IL-4 and IL-10 (Waaga et al,
2001).
An important finding ofmy study was that it failed to support the hypothesis
that the production of inhibitory cytokines such as IL-10 and TGF-P is associated
with DSH. I found that both cadaveric and living-related recipients with good graft
outcome appeared to produce lower levels of donor-specific IL-10 and there was no
significant correlation between IL-10 production and donor responsiveness or graft
outcome in either cohort. The immunosuppressive properties of IL-10 are well
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documented, as it can inhibit antigen presentation and CD4+ T cell proliferation in
vitro, as well as the generation of allo-specific cytotoxicity by virtue of its effects on
the costimulatory function of APC (Groux et al, 1998). However, IL-10 has also
been shown to have pro-inflammatory properties depending on the nature of the APC
and the local microenvironment. IL-10 does not block the initiation of an alloimmune
response by allogeneic DC and B cells (Nickerson, 1997). IL-10 also augments IL-2
supported proliferation of CD8+ T cells, thereby enhancing cytotoxicity (Chen et al,
1991; Groux et al, 1998). Therefore, IL-10 may be beneficial or deleterious
following transplantation. IL10 appears to have a dose-dependent effect on acute
GvHD lethality after bone marrow transplantation with both reduction (Baker et al,
1999; Holler et al, 2000) and exacerbation (Hempel et al, 1997; Blazar et al, 1998) of
GvHD being reported. IL-10 or IL-10 mRNA expression has also been associated
with acute rejection in some transplant models (Zheng et al, 1995; Xu, et al, 1995;
Qian et al, 1996; Lang et al, 1996). Together, my results suggest that the regulatory
mechanism underlying DSH may be independent of IL-10 and this could be tested by
assessing donor-specific proliferation in the presence of anti-IL-10 or anti-IL-lOR
antibody in patients who showed DSH.
The role of TGF-P in allograft acceptance and chronic rejection has been of
great interest in recent years. Although currently viewed as an immunoregulatory
cytokine (Letterio et al, 1998; Josien et al, 1998; Bickerstaff et al, 2000), TGF-P also
has pro-inflammatory and fibrogenic properties (Border et al, 1994; Hutchinson,
1999; Blobe, 2000). I found that good graft outcome in living-related recipients was
associated with lower levels of donor-specific TGF-P production compared with
patients with poor graft outcome and there was no correlation between DSH and
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donor-specific TGF-(3 production. In contrast, two groups have demonstrated TGF-P
dependent suppression of donor-specific DTH responses in renal transplant patients
who maintained good graft function without immunosuppressive therapy (Van
Buskirk et al, 2000; Lee et al, 2002). I also found that patients with chronic rejection
produced lower levels of donor-specific TGF-P than patients without chronic
rejection. In contrast, other studies have demonstrated that intra-graft TGF-P mRNA
correlated with interstitial fibrosis and chronic allograft nephropathy (Sharma et al,
1996; Suthanthiran et al, 1998). Additionally, Brenchley et al (1998) proposed local
activation of TGF-p may be a more important determinant of subsequent graft
fibrosis than the actual level of TGF-p as prolonged over-expression of TGF-P in the
vessels or interstitium of the graft may contribute to chronic rejection. Therefore it is
possible that the systemic production of TGF-P I measured may not reflect activities
within the graft even in patients with established chronic rejection.
Although I found no evidence to support a role for TGF-p in regulating
donor-specific immunity, I did find an association between TGF-P production and
immunosuppressive therapy. Patients treated with tacrolimus produced higher levels
of donor-specific TGF-P than cyclosporin treated patients, while patients on neither
drug produced almost undetectable levels of TGF-p. The effects of these drugs on
TGF-P production are controversial, as Shin et al (1998) reported that cyclosporin
enhances TGF-P production, while others found no evidence that cyclosporin
(Hughes et al, 1999; van der Mast, 2000) or tacrolimus (Hughes et al, 1999) induce
TGF-p production. As the measurement of TGF-p is technically difficult, these
conflicting results may be explained by differences in methodology with variable
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results reported using different immunoassays (Kropf et al, 1997). I measured active
TGF-p using a commercial ELISA kit, but analysed only a limited number of
patients and it would have been interesting to assess TGF-P production in the
cadaveric cohort where larger numbers of patients were available.
A criticism of many studies of cytokine production in transplantation has
been the use of PCR to assess cytokine gene expression in graft infiltrating cells, a
method which may not reflect cytokine protein production. Therefore, I performed
PCR studies in some patients to determine whether cytokine gene expression
correlated with donor-specific cytokine protein secretion. 1 used a non-quantitative
RT-PCR method, as I wished to simply establish whether the cytokine gene was
being expressed or not. However, this proved to be inconclusive, particularly when
TGF-P was assessed, as gene expression was often detected in autologously
stimulated cells as well as those in MLR. Furthermore, I could not achieve a reliable
PCR method for detecting 1L-4 mRNA, despite trying a number of different primers.
Most importantly, the PCR and ELISA data were frequently discordant and it might
be useful to use a quantitative PCR method so that donor-specific cytokine gene
expression could be related directly to control levels and to ELISA data.
To date, only a few case studies have reported the cytokines produced by
patients who show MLR-defmed DSH, all of whom were living-related renal
transplant recipients maintained on no immunosuppression due to malignancy or
because of non-compliance. Kusaka et al (1995) demonstrated high donor-specific
IL-4 production in a patient who received pre-transplant donor-specific blood
transfusions, while Ishido et al (1999) demonstrated lower levels of IFN-y and higher
levels of IL-4 after donor stimulation than after third party stimulation. Christensen
185
et al (1998) showed reduced mRNA expression of IL-2 and IFN-y in a patient with
post-transplant lymphoproliferative disorder. A more detailed report of intra-graft
cytokine production in cadaveric renal transplant recipients showed low levels of
both IL-2 and IL-10 in patients with stable graft function, high levels of IL-2 in
patients with acute rejection, and high levels of IL-10 and low levels of IL-2 in
patients with chronic rejection (Oliveira et al, 1998). In studies of liver transplant
patients, increased IL-2 and IFN-y production have also been found to be associated
with acute rejection (Minguela et al, 1999), while IL-4 and IL-10 were associated
with stable graft function (Chung et al, 1998). Together, these reports support my
findings of high donor-specific IL-4 and low IL-2 production in association with
DSH and good graft outcome, as well as my finding of high donor-specific IL-10
production in patients with chronic rejection.
MALIGNANCY COHORT
Ten cadaveric recipients who developed a de-novo solid organ malignancy after
transplantation were studied to assess the effect of immunosuppressive therapy and
to determine whether DSFI occurred in patients who maintained their grafts on low-
dose immunosuppression. Four of these patients maintained excellent graft function
only with prednisolone mono-therapy, while the other patients received low-dose
dual therapy. Significantly fewer patients in the malignancy group received
cyclosporin or azathioprine compared with cadaveric recipients without malignancy,
and none of the patients with malignancy were being treated with tacrolimus or
mycophenolate at the time of the study. Nevertheless, the patients with malignancy
shared many clinical features with the good outcome group of the cadaveric cohort
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without malignancy, including good graft function, a low acute rejection rate and a
similar incidence ofDSH.
The malignancy cohort also shared some immunological features of patients
with good graft outcome without malignancy, with both groups producing
significantly lower levels of IL-2 in response to donor stimulation compared with
patients with a poor graft outcome. However, low levels of donor-specific IL-4 were
found in patients with malignancy in contrast to the high donor-specific IL-4
production I found in cadaveric recipients without malignancy with good graft
outcome. A striking finding in the malignancy group was the production of
approximately four-fold higher levels of IL-10 in response to donor stimulation than
any other cytokine. IL-10 has been implicated in both the development of EBV-
associated post-transplant lymphoproliferative disorder (PTLD) and the induction of
a state of operational tolerance in patients who maintained their grafts after
discontinuation of immunosuppression (Birkeland et al, 2000). MLR-defined DSH
was found in 4/5 of these patients, although chronic rejection developed in two of
these patients after successful treatment for PTLD. As EBV encodes a polypeptide
analogous in structure and bioactivity to human natural IL-10, viral IL-10, and the
ELISA assay detects both sources of IL-10, it is difficult to determine the source of
IL-10 in these patients. Furthermore, as IL-10 levels increased prior to the diagnosis
of PTLD and fell after cancer treatment, it is possible that viral IL-10 may account
for these findings. However, in view of my previous results in patients without
malignancy, it is unlikely that high donor-specific IL-10 production itself could
explain the development of DSH in my sub-group of patients with malignancy. In
addition, as I found low levels of IL-4 in my malignancy cohort, it is possible that
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other factors might be important in maintaining DSH and it would have been
interesting to evaluate TGF-(3 production in these patients for evidence of
immunoregulation.
Although there are a number of possible mechanisms for the development of
malignancy post-transplantation, CD4+CD25+ T cells which are essential in
maintaining self-tolerance, may play an important role in the down-regulation of
tumour immunity (Tanaka et al, 2002; Wood et al, 2003). These cells may act to
impede the generation of effective immunity against autologous tumours and host
responses have been shown to be augmented by the depletion of these cells (Shimizu
et al, 1999; Tanaka et al, 2002). CD4+CD25+ T cells appear to mediate their
suppressive effects by a cytokine-independent and cell contact dependent
mechanism, therefore their activity is likely to be independent of IL-10. These
regulatory cells might also help to explain the high frequency ofDSH that I found in
my malignancy cohort, which could have been mediated by the same mechanism.
PROSPECTIVE STUDY
Most previous reports on DSH have been prospective studies which compared pre-
transplant donor-specific responses with those 6-51 months post-transplantation,
although most studies ended at 12 months after transplantation (Bas et al, 1992;
Reinsmoen et al, 1993; Ghobrial et al, 1994; Creemers et al, 1997; Kerman et al,
1997). Frequent serial laboratory analyses over a prolonged period is the ideal way
to explore this group, but this is rarely feasible in practice due to financial and time
restraints, and I was only able to perform the immunological assays for up to one
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year after transplant. However, the clinical course of patients was followed for 2
years post-transplantation to determine whether stable graft function was maintained
and I also considered that my period of 1-year follow-up was appropriate as any
prognostic laboratory test for tailoring immunosuppression would be of greatest
value within this time.
My study population consisted of eighteen renal allograft recipients (14
cadaveric and 4 living-donor), all of whom received standard triple
immunosuppressive therapy. At the end of the first year post-transplant, 11/18
patients (9 cadaveric and 2 living-donor) met the clinical criteria for good graft
outcome that I had defined in the retrospective study. Four patients (3 cadaveric and
1 living-donor) met the clinical criteria for poor graft outcome, and the remaining
three patients did not meet the pre-determined criteria for either outcome group. The
acute rejection rate appeared to be higher among living-donor than cadaveric
recipients (75% versus 33%), but this is probably due to the small size and
heterogeneity of the living-donor group, which consisted of only one HLA-ID, two
HLA-HI and one NI recipients.
I found that three cadaveric recipients, who all received well-matched grafts
and had no acute rejection episodes, showed a RRI < 28% immediately pre-
transplant, but only one of these patients continued to show DSH at one year post-
transplant. As the level ofRRI in the two patients who did not show DSH was 30%
and 32% at 12 months post-transplant, it is possible that random fluctuations in
donor-responsiveness are responsible for this finding, and it would have been
interesting to follow them for a longer period to determine whether they would
develop DSH with a RRI < 28% in the future. Such fluctuation were seen in most of
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my patients and as all samples for each patient were analysed simultaneously, they
may, at least in part, be attributable to the changes in immunosuppressive therapy
which occurred during the course of my study. Similar fluctuations were also
observed by another group who analysed patients serially (Ghobrial et al, 1994).
I found DSH in three cadaveric recipients at three months after transplant, in
four patients at six months and in five patients at 12 months, and DSH was
maintained in all these patients throughout the study period. In previous prospective
studies of cadaveric recipients, DSH has been detected as early as three months post-
transplant (Reinsmoen et al, 1990; Bas et al, 1992), although another group found
that the mean time to the development of DSH was 21 ± 9 months post-transplant
(Kerman et al, 1997). The only living-donor recipient who developed DSH in my
study received an HLA-ID graft and showed an RRI < 28% immediately pre-
transplant which was maintained throughout the first year post-transplant. This is in
keeping with previous reports that 95-100% ofHLA-ID recipients showed DSH prior
to transplantation (Kahan et al, 1989; Kerman et al, 1997).
At the end of the first year post-transplant, DSH was found in 6/18 (33%)
patients overall, comprising 5/14 (36%) cadaveric recipients and 1/4 (25%) living-
donor recipients. As outlined in Chapter 1, the reported incidence of DSH in
cadaveric recipients is variable, but groups who have assessed MLR-defined DSH
over a period of 1 year, as I did, have found the incidence to range from 25%
(Reinsmoen et al, 1993) to 58% (Ghobrial et al, 1994). This wide variation may be
attributable to the use of homozygous typing cells (Reinsmoen et al, 1993) rather
than the original donor cells (Ghobrial et al, 1994) as stimulators in MLR. An
incidence of 56% using donor cells at 2 years post-transplant has also been reported
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(Creemers et al, 1997). Although the incidence of DSH in HLA-HI recipients has
been reported to be 27%-47% at 12 months post-transplant (Reinsmoen et al, 1993;
Kerman et al, 1997), neither of the HLA-HI recipients in my study group showed
DSH.
In contrast to my findings in the retrospective cadaveric cohort, I found no
significant difference in serum creatinine levels in the prospective study between
patients who showed DSH and those who did not throughout the first two years post-
transplant. However, as many others have reported (Grino et al, 1990; Reinsmoen et
al, 1993; Ghobrial et al, 1994; Kerman et al, 1997; Creemers et al, 1997), the patients
in my prospective cohort who developed DSH experienced significantly fewer acute
rejection episodes than patients who did not (17% versus 58%). However, one
patient who showed DSH developed biopsy-proven chronic rejection, as well as one
patient who did not show DSH. At the end of the first year post-transplant, only 3/6
patients (all cadaveric recipients) who showed DSH had good graft function and all
continued to maintain excellent graft function at two years post-transplant.
Donor-specific cytokine production has not been assessed previously during
the development of DSH, which would be important to show if DSH is indeed
associated with a shift from Thl to Th2 cytokine production as is widely speculated.
It would also be important to assess how early the production of cytokines may
predict graft outcome. At all time points I examined, patients who developed DSH
produced lower levels of donor-specific IL-2 than patients who did not develop DSH,
although this only reached statistical significance immediately pre-transplant. Both
patients with and without DSH produced higher levels of IL-2 in response to third
party than donor stimulation at all time points. The DSH group also produced lower
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levels of donor-specific IFN-y throughout the 12-month study period compared with
those who did not develop DSH, but these differences were only statistically
significant at 6 and 12 months post-transplant. IFN-y production was higher after
third party than donor stimulation in the DSH group but higher after donor than third
party stimulation in the non-DSH group at all time points. These findings are
generally consistent with the significant correlation between RRI and donor-specific
IL-2 and IFN-y production I found in the retrospective group.
In the prospective cohort, donor-specific IL-4 production generally rose
throughout the study period, but the DSH group appeared to produce higher levels of
IL-4 pre-transplant and at 12 months after transplant than the non-DSH group. This
is in keeping with the association between DSH and high donor-specific IL-4
production and the correlation between RRI and donor-specific IL-4 production that I
found in long-term cadaveric graft survivors of the retrospective cohort. In addition,
the patients with good graft outcome produced lower levels of IL-2 and higher levels
of IL-4 in response to donor stimulation, as I found in the cadaveric cohort. As
noted earlier, IL-10 producing regulatory T cells have been implicated in transplant
tolerance (Hara et al, 2001; Kingsley et al, 2002), but I found no correlation between
DSH and IL-10 production in either arms ofmy study.
The consistent finding in both arms of my study was low donor-specific IL-2
and high IL-4 production in cadaveric recipients with DSH who maintain good graft
function after one year post-transplant and in long-term graft survivors. This may
reflect good HLA-matching, as HLA-DR compatibility was a significant factor in the
retrospective cadaveric group and five of the six patients in my prospective study
who developed DSH had no mismatches at the HLA-DR locus. The low production
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of IL-2 in patients who showed DSH could not be attributed to treatment with
calcineurin inhibitors, as similar numbers of patients who did not show DSH were
treated with cyclosporin. As discussed above, IL-4 may be required to maintain DSH
by promoting the development of Th2-like regulatory cells, while low levels of
donor-specific IL-2 may facilitate apoptosis of alloreactive cells and the development
of regulatory T cells, thereby providing a balance between regulation and deletion of
alloreactive responder cells.
TAILORING OF IMMUNOSUPPRESSION
The benefits of reduction of immunosuppression must be weighed against the risk of
acute rejection and potential graft loss. The optimal time for reduction of
immunosuppression is unknown, but as I found fluctuations in the RRI within the
first 12 months post-transplant and the risk of acute rejection is highest during this
early period, tailoring of immunosuppression may be best considered at one year
post-transplantation. Although clinical factors play an important role in the decision
to tailor immunosuppression, they are of limited value as precise predictive factors
(Schulak et al, 1990; Hricik et al, 1993; Silkensen et al, 2001). Good graft function
does not always imply low donor responsiveness and an isolated raised serum
creatinine level is not necessarily an accurate guide, as it is sometimes a late
indicator of graft dysfunction and can be affected by non-immunological factors.
The ultimate aim of my work was to determine whether the assessment of donor-
specific cytokine production in stable renal transplant recipients who show DSH
would be of value for tailoring immunosuppression.
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Many groups have suggested that the testing ofT cell reactivity could be used
to select patients for reduction of immunosuppression, but did not test this hypothesis
directly (Reinsmoen et al, 1993; Zanker et al, 1993; Ghobrial et al, 1994; DeBruyne
et al, 1995; Creemers et al, 1997). Furthermore, the few studies that have assessed
the effects of reducing immunosuppression on donor-specific cell reactivity have
produced conflicting results, as some reports have shown a good correlation between
clinical outcome and in vitro responsiveness (Goulmy et al, 1991; Beik et al, 1997;
van Besouw et al, 2000), but others have failed to do so (Mazariegos, et al, 1995;
Creemers et al, 1998). The lack of consistency in these studies may be due to
differences in the methods used to assess donor reactivity and in the duration of
patient follow-up. To date, only one centre has used MLR-defined DSH to select
patients for reduction of immunosuppression, but this group reported acute rejection
episodes and graft losses even among HLA-ID recipients (Fletchner, 1984; Kahan,
1989; Kerman, 1997).
I have extended these earlier studies by performing retrospective and
prospective studies to determine whether the analysis of donor-specific cytokine
production would be of additional value to the detection of DSH by MLR and to
determine whether this could be applied to both cadaveric and living-related
recipients. In the retrospective study, I found that cadaveric recipients who showed
DSH produced approximately two-fold higher levels of donor-specific IL-4 than IL-2
irrespective of the level of graft function and that patients who did not show DSH
produced a low IL-4/ IL-2 ratio, even in the presence of good graft function. These
findings suggested that the production of a high donor-specific IL-4/ IL-2 ratio was
more in keeping with the presence of DSH than the level of graft function, and that
194
graft function may be influenced by other factors. However, of the sixteen long-term
cadaveric recipients I identified with DSH and good graft function, only nine patients
produced higher levels of IL-4 than IL-2 after donor stimulation and the ratio of
donor-specific IL-4/ IL-2 production in these patients was 3.7. In the prospective
arm of the study, I found four-fold higher levels of donor-specific IL-4 than IL-2
only in the three cadaveric recipients with DSH who maintained good graft function
at 12 months post-transplant. Therefore, the consistent finding in both arms of my
study is the detection of a high donor-specific IL-4/ IL-2 ratio in patients with DSH
and good graft function, but this applied to only cadaveric recipients. On the basis of
my results, it could be suggested cadaveric recipients who showed DSH and maintain
good graft function with no late acute rejection episodes, could be considered for
reduction of immunosuppression if they produce approximately four-fold higher
levels of IL-4 than IL-2 after 12 months post-transplant.
The utility of cytokine analysis in living-related recipients may be limited.
Low donor-specific IL-2 production was associated with good graft outcome in the
retrospective cohort, but this could not be confirmed in the prospective cohort.
Furthermore, I found DSH and good graft outcome in six patients, five of whom
were recipients of HLA-ID grafts, but I found no association between DSH and
cytokine production in either arm of my study. Therefore, the degree of HLA-
compatibility appears to an important factor in the development of DSH and graft
outcome. HLA-NI recipients are unlikely to be good candidates for reduction of
immunosuppression, as the risk of acute rejection would outweigh the potential
benefit, unless under exceptional circumstances such as malignancy.
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I conclude that there is unlikely to be a single immunological test or clinical
parameter that will allow safe reduction of immunosuppression. As previous studies
have suggested, the detection of DSH as judged by poor proliferation in MLR, is not
alone sufficient to predict long-term graft outcome and to guide clinical decisions,
even among HLA-ID living-related recipients. However, my results do suggest that
the presence ofDSH, together with low donor-specific IL-2 and high IL-4 production
in the presence of stable graft function at one year post-transplant, may be indicators
of cadaveric recipients who are at low risk of adverse events. In living-related
recipients, patients who receive HLA-ID grafts are the best potential candidates for
tailoring of immunosuppression, as DSH is usually found and good outcome is
associated with low donor-specific IL-2 production.
FUTURE WORK
My study has probably given rise to more questions than answers, but perhaps the
most glaring unanswered questions are whether regulatory cells or inhibitory
cytokines, such as IL-10 and TGF-fi mediate DSH. Certainly, I was unable to
provide evidence of a correlation between DSH and donor-specific TGF-p
production, as analysis was limited to the living-donor retrospective cohort which
generally produced low levels of all cytokines in response to donor stimulation.
Therefore, I anticipate that it would be more useful to perform future work on
cadaveric recipients.
I propose that a prospective study of first cadaveric graft recipients over 2 or
more years with frequent serial immunological analyses, to detect DSH and measure
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donor-specific IL-2, IL-4, IL-10 and TGF-P production by quantitative PCR and
ELISA, would help to answer these questions. A quantitative PCR method would
overcome some of the hazards of measuring TGF-P by ELISA, and provide useful
confirmation of other ELISA results. It would be particularly interesting to see
whether patients who produce low levels of donor-specific IL-2 and high levels of
IL-4 pre-transplant would also have high IL-10 and TGF-P mRNA expression.
Further work could focus on the nature of the cytokine-producing cells and sorting
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